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Abstract  
 
Background Psychological interventions may be beneficial for bipolar disorder. 
 
Aims Efficacy evaluation of psychological interventions for adults with bipolar disorder. 
 
Methods A systematic review of randomised controlled trials.. Outcomes were meta-
analysed using RevMan and confidence assessed using the GRADE-method. 
 
Results We included 55 trials with 6010 participants. Moderate quality evidence associated 
individual psychological interventions with reduced relapses at post-treatment and follow-up, 
and collaborative care with a reduction in hospitalisations. . Low quality evidence associated 
group interventions with fewer depression relapses at post-treatment and follow-up, and 
family psycho-education with reduced symptoms of depression and mania   at post-treatment. 
 
Conclusions There is evidence that psychological interventions are effective for people with 
bipolar disorder. Limits were the very low quality of much of the evidence and therefore 
inconclusive. Further research should identify the most (cost)-effective interventions for each 
phase of this disorder. 
 
Declaration of interest:  RM and SJ are author on three included studies. . 
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Introduction 
Bipolar disorder affects approximately 1.5% of the population, (1-5) and often takes a 
chronic course with recurrent manic, hypomanic, depressive, and mixed episodes. Bipolar 
disorder is associated with poor psychosocial functioning, (6) a high economic burden, (7-10) 
and early mortality. (11) People with bipolar disorder are symptomatically ill almost half of 
the time. (12) Although mania often results in hospitalisation, (13) depressive symptoms and 
episodes account for most illness-related disability. (1) In trying to long term manage the 
illness  people with bipolar disorder use pharmacological interventions , but 60% of 
outpatients that start with maintenance treatment will have an episode within two years. (13) 
As an additional strategy, many people with bipolar disorder wish to use psychological 
interventions to improve symptoms and to reduce relapse rates. Previous meta-analyses have 
evaluated evidence for a specific psychological intervention  (e.g., cognitive behavioural 
therapy (CBT), (14-18) family interventions, (17, 19) and psychoeducation (17, 18))  some 
during acute episodes and some during euthymic periods, with varying duration of 
intervention and follow-up. The number of relevant trials has tripled since the last meta-
analyses, and a current review is needed to inform the selection of psychological 
interventions for each stage of bipolar disorder. . Given the need for a comprehensive 
evaluation, we conducted a systematic review and meta-analysis of psychological 
interventions for adults with bipolar disorder compared with control groups (treatment-as-
usual, waitlist, attention control or an active intervention) on symptoms of depression and 
mania, response, relapse, discontinuation, hospitalisation, quality of life, and psychosocial 
functioning. This review informed the National Institute for Health and Clinical Excellence 
(NICE) guideline on the management of bipolar disorder (20) and the related Dutch 
Nederlandse Vereniging voor Psychiatrie (NVvP) and Trimbos-institute guideline, and the 
review is reported here following PRISMA guidelines. (21) 
Methods 
Eligibility criteria 
We included randomised controlled trials of all individual, group, and family 
psychological interventions for adults (18 years and older). We also included service-level 
intervention with (elements of) psychological interventions (e.g. collaborative care).  Eligible 
comparison groups were control groups (treatment-as-usual, waiting list or attention control) 
or other active interventions. Trials were eligible if at least 66% of the participants had 
bipolar disorder or if disaggregated data were reported for participants with bipolar disorder.  
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For trials also including participants with other mental disorders (e.g. unipolar depression or 
schizophrenia), we requested disaggregated data.  
Search strategy 
We searched CINAHL, Embase, Medline, PreMedline, PsycINFO, CDSR, DARE, HMIC, 
and CENTRAL from inception to January 2014 using terms for bipolar disorder and 
randomised clinical trials. (Appendix 1) Searches were not restricted by language. MO and 
RB assessed the eligibility of studies for inclusion and discussed disagreements with a third 
author (EMW). After our search, we searched the reference lists of the included studies, 
excluded studies, and previous reviews. We contacted study authors and experts to request 
additional reports of trials. 
Assessment of bias 
Studies were assessed and rated independently by two authors (MO, PC) using the 
Cochrane Collaboration Risk of Bias Assessment Tool. (22) Disagreements were discussed 
with a third author (EMW) and resolved by consensus. Each study was rated for risk of bias 
owing to sequence generation; allocation concealment; blinding of participants, assessors, 
and providers; selective outcome reporting (e.g., reporting incomplete data or not all of the 
outcomes measured); and incomplete data. Risk of bias for each domain was rated as high 
(seriously weakens confidence in the results), low (unlikely to seriously alter the results), or 
unclear.  
Data management 
Service user outcomes included reduction of symptoms of depression and mania 
(response), relapse (any type, depression, mania or mixed), hospitalisation, quality of life, 
suicide, psychosocial functioning, and study discontinuation. We also extracted treatment 
format, number and length of sessions, method of recruitment, inclusion and exclusion 
criteria, age, sex, setting, study location and number of people with bipolar I disorder. For 
each study, the important study characteristics are reported in table 1.  
Treatment in the acute phase typically aims at remission of the index episode, and if 
symptoms of the index episode reappear after a short period, the term "relapse" is often used. 
Long-term management aims to prevent future episodes, which are often called “recurrence”. 
(23) In this review, it was impossible to distinguish between “relapse” and “recurrence” 
because studies included both acutely symptomatic and euthymic participants without 
reporting disaggregated data; we have used the term "relapse" for both outcomes. 
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Statistical analysis 
Psychological treatments developed for bipolar disorder may differ in the underlying 
therapeutic tradition (e.g. cognitive behaviour therapy, interpersonal therapy, 
psychoeducation) and delivery, but they share non-specific treatment factors (e.g. contact 
with a caring professional),(24) so their effects may be aggregated in meta-analysis to explore 
the range of potential effects. In this review, psychotherapies were aggregated by methods of 
delivery, including individual treatments, group treatment, family therapy, and collaborative 
care. Information about the effects of interventions with different therapeutic traditions were 
analysed in subgroups.     
For continuous outcomes, we calculated the standardised mean difference (SMD), 
Hedges’s g, for between-group differences. For dichotomous outcomes, we calculated the 
risk ratio (RR) for events. All outcomes are reported with 95% confidence intervals. Overall 
effects were calculated using random effects models. Continuous effects were weighted by 
the inverse of variance; dichotomous effects were weighted using the Mantel-Haenszel 
method. (22)  Because time-to-event data were reported inconsistently, and often 
incompletely (e.g. as curves without associated events or statistics), we were unable to 
analyse these results; however, most studies were short and similar in duration, and hazard 
ratios would be similar to the relative risks reported here. 
Missing data were noted for each outcome. When missing cases were not reported, we 
contacted the authors. If continuous outcomes were reported for completers as well as 
controlling for missing data (for example, imputed using regression methods), we used the 
data that controlled for missing data.  
Statistical heterogeneity was assessed by visual inspection of forest plots, by performing 
the χ2 test (assessing the P value), and by calculating the I2 statistic, which describes the 
percentage of observed heterogeneity that would not be expected by chance. If the P value 
was less than 0.10 and I
2
 exceeded 50%, we considered heterogeneity to be substantial. Meta-
analyses of comparisons and subgroups were conducted using RevMan 5.2, (25) due to the 
few studies per type of intervention a meta-regression would not be meaningful and is 
therefore not conducted. Confidence in the results was assessed by MO and EMW using the 
GRADE method, (26) which is a structured assessment of the quality of evidence attending to 
the following factors: risk of bias, inconsistency, indirectness, imprecision, and publication 
bias. 
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Results 
Trial flow 
Of 13,641 potentially relevant citations and four from other sources, we retrieved 59 
papers, which were assessed for inclusion (Figure 1). Of these, three were excluded because 
only a minority of participants had bipolar disorder and we could not obtain disaggregated 
data, (27-29) and one was a trial of a measurement instrument. (30) Fifty five randomised 
controlled trials were, therefore, included, of which three were unpublished (31-33) at time of 
inclusion, one has recently been published and the others were published between 1984 and 
2014. Seven were not included in the meta-analysis because they did not report useable 
outcomes, which remained unavailable after contacting the authors. (34-40) 
Study characteristics  
Table 1 presents study characteristics for each trial. Included studies randomised 6010 
participants, ranging from 19 to 441 per study.  Studies were conducted in North America 
(k=22), England and Ireland (k=12), Central Europe (k=11), Australia (k=5), Brazil (k=3), 
and Iran (k=2). Participants were recruited from outpatient (k=23) or inpatient settings 
(k=12), GP practices (k=2), Community Mental Health Teams (k=2), or advertising 
combined with (self) referral (k=16). In 52 studies a diagnostic interview was used to 
establish the presence of bipolar disorder, in one study participants themselves reported if 
they had bipolar disorder, another confirmed the diagnosis through a questionnaire, and one 
study only reported that bipolar disorder was an inclusion criterion. 
Across all trials, the median of the mean age of participants was 40 years (range 26 to 55), 
the median percentage who were female was 58% (range 1% to 77%) and the median 
percentage of participants with bipolar I disorder was 81% (range 42% to 100% and one 
study with 0%).  Four studies included participants experiencing a depressive episode at 
baseline, (41-44) six studies included both participants experiencing depressive and manic 
episodes, (35, 36, 45-48) and 32 studies included only euthymic participants. Twelve studies 
(38, 39, 49-58) included a mix of euthymic and symptomatic participants at baseline, of 
which only two studies (49, 58) provided disaggregated data.  
Interventions 
Trials included a variety of interventions (Table 2) and comparison conditions and were 
grouped in nine comparisons. The first five comparisons were interventions compared with 
treatment as usual (individual treatment, group treatment, family therapy, collaborative care, 
integrated cognitive and interpersonal therapy). Four comparisons included interventions 
compared with other active interventions (“head-to-head” trials).  
7 
 
Outcomes 
Table 3 lists the continuous measures used in the trials by outcome type. Dichotomous 
data were also reported. Response was determined through clinical interviews (e.g. SCID), 
cut-off points on diverse scales (e.g. when scoring symptomatic at baseline and at a follow-up 
scoring on the YMRS<11 for manic response or Bech–Rafaelsen scores < 6 for depression 
response) or a percentage of reduction on a scale (e.g. 50% on the HAM-D for a depression 
response). In most trials, participants had to score above a cut off score for a period of time 
(e.g. two months) to be considered responsive. Relapse in most cases was determined with a 
clinical interviews, for example with the Structured Clinical Interview for DSM (SCID-
LIFE), Schedule for Affective Disorders and Schizophrenia (SADS) and the Mini-
International Neuropsychiatric Interview (M.I.N.I.). Other trials established relapse in 
participants with a score above a cut-off point on a depression (e.g. HAM-D>12) or mania 
scale (e.g. YMRS>20 for mania); in some, a combination of the two scales was used to 
evaluate the presence of mixed episodes. Five studies assumed that a relapse had occurred 
based on chart reviews or hospitalisation records.  
Risk of bias  
Each risk of bias item is presented as percentages across all studies in table 4 and for each 
studied independently in table 5. No trials were at high risk of bias for random sequence 
generation; however, the method of randomisation was not reported in 15 trials. Allocation 
concealment was unclear in 25 trials and low risk in 30 trials. Blinding of participants and 
providers in trials of psychological interventions is impossible, so all were at high risk of bias 
per se. Nine trials only used self-report measures and 32 trials reported blind assessor rated 
outcomes, these 41 trials were at low risk of bias for blinding. However, eight studies did not 
have blinded assessors and these were considered to be at high risk of bias. In six studies, it 
was unclear if assessors were blinded. For incomplete outcome data, 25 trials were at low risk 
of bias and 24 were at high risk of bias because of the number (more than 10%) of missing 
cases or because missing cases were excluded from the analyses. In six studies, the handling 
of missing data was not described.  
Reporting bias  
Risk of reporting bias could not be assessed indirectly (e.g., using funnel plots or statistical 
methods) because there were few studies for most comparisons and the studies were of 
similar size. We used direct methods to assess risk of reporting bias by checking trial 
registrations and by contacting authors.  There was a high risk of reporting bias in 22 trials, 
including seven studies that did not report any usable data. In addition to the outcomes we 
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analysed, several trials also reported incomplete results that could not be included in the 
meta-analysis. Only 11 studies were prospectively registered, but 23 others were assessed to 
be at low risk of bias because authors provided missing data or confirmed that all outcomes 
were published.  
Overall quality of the evidence 
Using the GRADE method, (26) many outcomes were downgraded because of risk of bias 
(e.g., inappropriate handling of missing data). Nearly all results were downgraded at least one 
level because of imprecision (the analyses included few participants or events). Results for 
relapse following individual interventions, hospitalisation following collaborative care, and 
study discontinuation during interpersonal and social rhythm therapy were of moderate 
quality. Most other evidence was of low or very low quality.  Studies also reported controlled 
comparisons at follow-up, but most outcomes were of very low quality. 
Quantitative data synthesis   
Across nine comparisons, results of the meta-analyses suggest that psychological 
interventions may be associated with symptomatic improvement, and fewer relapses and 
hospitalisations. The majority of these low to moderate quality outcomes are summarized per 
comparison and presented in table 6 (post-treatment) and table 7 (follow-up) with reasons for 
downgrading, for all outcomes per comparison and subgroups we refer to Table 8 and 9.  
 
Individual psychological interventions 
The search identified 15 RCTs (n=1580) of face-to-face and interactive online 
psychoeducation (49, 58-63) cognitive (behavioural) therapy (33, 41, 50, 51, 64-67) and 
medication adherence therapy. (68) Interventions were compared with treatment as usual. 
Eleven trials enrolled participants who were euthymic at baseline, four trials enrolled a mix 
of participants experiencing acute episode of mania or depression and participants who were 
euthymic. (49-51, 58)   
Seven trials (n=637) reported low quality evidence that individual psychological 
interventions were associated with a small reduction in symptoms of depression at post-
treatment. (49, 50, 58, 64-67) Six trials (n=365) reported moderate quality evidence that 
individual psychological interventions reduced the risk of relapse at post-treatment. (50, 63-
65, 67, 68) However, three trials found no difference in effect on symptoms of mania. (64, 
66, 67) One trial with few events was inconclusive regarding the risk of hospitalisation. (68) 
Eight trials (n=532) reported moderate quality evidence that individual psychological 
interventions were associated with a reduction in relapse at follow-up. (58, 62-65, 67, 68) 
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There was low quality evidence from three trials (n=214) that individual psychological 
interventions might be associated with a reduction in hospitalisations, but the confidence 
interval was compatible with both a reduction and an increase in the effect. (33, 63, 67, 68)  
 
Group psychological interventions 
The search identified 12 RCTs (n=914) of group interventions including psychoeducation, 
(47, 69-72) cognitive behavioural therapy, (31, 73, 74) mindfulness therapy, (75, 76) social 
cognition and interaction training, (77) and dialectical behaviour therapy. (42) Interventions 
were compared with treatment as usual except for two studies that compared psychoeducation 
with attention control. (69, 70) In ten trials participants were euthymic at baseline (31, 69-
77), one study included participants experiencing an acute episode of mania or depression 
(47) and another included people who were currently depressed.  
Eight trials (n= 423) reported very low quality evidence of a small effect on depression 
outcomes at post-treatment favouring group interventions. (31, 42, 47, 72, 74-77) Six trials 
(n=375) found no effect on manic symptoms. (31, 47, 72, 74, 75, 77) Furthermore, the two 
studies comparing psychoeducation to attention control (n=170) found low quality evidence 
for a reduction in any type of relapse, but the confidence interval was compatible with both a 
reduction and increase in the effect. (69, 70) The two studies did find evidence for a reduction 
in depressive and manic relapses. Also, the two studies together with a trial comparing CBT 
with treatment as usual (n=205) reported low quality evidence that group interventions might 
be associated with a reduction in hospitalisations, but the confidence interval was compatible 
with both a reduction and increase in the effect. (69, 70, 74) 
Results at follow-up in five studies (n=333) reported low quality evidence of a reduction 
in depressive relapses. (69, 70, 72, 73, 75) Also, four studies (n=274) reported a reduction of 
relapses into mixed episodes. (69, 70, 72, 73) However, effects on depressive symptoms (31, 
72, 75) and hospitalisation  (69, 70) were inconclusive.  
 
Family psychoeducation 
The search identified seven RCTs (n=409) of family psychoeducation. Two trials included 
psychoeducation for participants and their family members (48, 78) and in five trials only 
family members received psychoeducation. (56, 79-82) Interventions were compared with 
treatment as usual. Five trials enrolled participants who were euthymic at baseline, one trial 
enrolled participants who were experiencing acute episode of mania or depression or were 
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euthymic at baseline (56) and another included only participants who were in an acute 
episode of mania or depression. (48) 
One trial (n=43) found low quality evidence of medium effect in reduction of depressive 
and manic symptoms favouring family psychoeducation at post-treatment. (56)   
At follow-up, three trials (n=228) reported low quality evidence of a reduction in relapse. 
(78, 79, 81)  One trial (n=113) reported a reduction in manic relapses. (81) One study (n=57) 
reported a very large effect on reduction of the number of hospitalisation, but there were only 
nine events in the study. (79)  
 
Collaborative care  
The search identified five RCTs (n=1058) on collaborative care compared with treatment 
as usual. Two trials on collaborative care started with euthymic participants, (45, 83) three 
trials recruited participants in an episode. (52-54)   
In comparison to treatment as usual, two trials (n=123) reported low quality evidence of 
small effect favouring collaborative care on depressive symptoms and no effect on manic 
symptoms at post-treatment, but the effect estimates were imprecise. (52, 53) One trial 
(n=234) found no difference in reduction of relapses. (54) However, two trials (n=572) 
reported moderate quality evidence suggesting collaborative care reduced the number of 
hospitalisations at post-treatment. (54, 83)  
 
Integrated Cognitive and Interpersonal Therapy 
The search identified one RCT (n=212) with a group of participants that were randomised 
to integrated cognitive and interpersonal therapy or treatment as usual. (32) Participants in the 
intervention group could choose to follow individual or group integrated cognitive and 
interpersonal therapy. Outcome data were presented for the whole intervention group versus 
treatment as usual. 
The trial reported low quality evidence at post-treatment of a medium effect favouring the 
intervention on depressive symptoms and no effect on manic symptoms.  
 
Family-focused therapy  
The search identified four RCTs (n=357) on family focused therapy compared with 
psychoeducation, collaborative therapy or treatment as usual. Participants who were either 
euthymic, (84) in an episode or euthymic, (55) only depressed (41), or in any type of episode. 
(48)     
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Post-treatment data were of low quality. One study (n=79) found no effect of family 
focused therapy compared with treatment as usual on manic symptoms and a medium effect 
on depressive symptoms (although the confidence interval was also compatible with no 
effect). (55) A small effect was found on relapse in a study (n=53) comparing family focused 
therapy with psychoeducation, but the confidence interval was compatible with both a 
reduction and increase in the effect. (84) The confidence in the follow-up results were very 
low.  
 
Cognitive behavioural therapy versus supportive therapy 
The search identified one RCT (n=76) comparing individual cognitive behavioural therapy 
with supportive therapy, the quality of the evidence was low. (85) At post-treatment a 
medium effect was found of supportive therapy on depressive symptoms. Also a small effect 
was found of supportive therapy on manic symptoms, but cognitive behavioural therapy 
reduced the risk of relapses. However, the confidence intervals for the mania and relapse 
outcomes were compatible with either a reduction or increase in the true effect. 
 
Interpersonal and social rhythm therapy (IPSRT) versus (active) control  
The search identified three RCTs (n=299) of interpersonal and social rhythm therapy 
(IPSRT) compared with quetiapine, intensive clinical management or treatment as usual. 
Participants in all three trials were in a depressive episode at baseline.(41, 43, 46)  
One study reported a small effect of quetiapine compared to interpersonal and social 
rhythm therapy on symptoms of depression at post treatment, but the confidence interval was 
compatible with both a reduction and increase in the effect. (43) A trial (n=41) of 123 weeks 
found effects that were in favour of intensive clinical management compared to interpersonal 
and social rhythm therapy on a reduction in relapses, but the confidence interval was 
compatible with both a reduction and increase in the effect. (46) All results were of very low 
quality. 
 
Integrated group therapy versus group drug counselling 
The search identified one RCT (n=61) including people with both bipolar disorder and a 
comorbid substance abuse disorder who were either euthymic or acutely depressed at 
baseline.  It compared integrated group therapy with group drug counselling. (57) At post-
treatment there was very low quality evidence of a small effect on depressive and manic 
symptoms, but confidence intervals were compatible with either reductions or increases in 
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symptoms. There was very low quality evidence of a moderate effect on manic symptoms at 
follow-up. 
 
DISCUSSION 
This is the first comprehensive systematic review and meta-analysis of the full range 
of psychological interventions that have been evaluated for the treatment of people with 
bipolar disorder. The evidence suggests that some, but not all, psychological treatments 
reduce relapse rates and hospitalisation, and they may improve depressive symptoms. In 
particular, we found moderate quality evidence that individual psychological interventions 
are associated with a 34% reduction in the risk of relapse at the end of treatment, sustained at 
26% reduction in risk at follow-up. There was also low quality evidence that individual 
psychological treatment reduced symptoms of depression, but the reduction may be small. 
Although the evidence is not as robust, group psycho-education also shows beneficial effects 
for reducing risk of relapse, and perhaps for some symptomatic improvement. We also found 
a substantial reduction in relapse rates for people who received family psycho-education, 
although the quality of the evidence for this finding was also low. In addition, our analysis of 
collaborative care shows moderate quality evidence for a 32% reduction in hospitalisation. 
We found little impact on symptoms of mania, quality of life, psychological functioning or 
other treatment outcomes, although in most cases the underpinning evidence was very low 
quality and therefore inconclusive. Moreover, we found no evidence of benefit for other types 
of psychological interventions such as interpersonal and social rhythm therapy.  
These results confirm and extend the findings of previous, smaller and narrower 
reviews of specific psychological treatments for bipolar disorder; (14, 15, 17-19) and suggest 
that, as the size of the evidence base has increased, the beneficial effects of some 
psychological interventions have become more apparent. Previous reviews included 10 or 
fewer trials and fewer than 1000 participants; by contrast, this review analysed 55 trials 
including data from 6010 participants. Overall, on the basis of this review, we would 
recommend the use of psychological interventions in the treatment of people with bipolar 
disorder to reduce relapse rates and to reduce depressive symptoms. Although there is not 
sufficient evidence to recommend a specific treatment over the others, the best evidence is for 
individual structured psychological interventions, and there is weaker, but still promising, 
evidence for group and family interventions, and for collaborative care. 
These results are consistent with other recent reviews showing that psychological 
approaches may reduce transition to psychosis, including for people with bipolar disorder, 
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(86) and that family psychological interventions reduce relapse rates in people with early (87) 
and established schizophrenia. (88) Additionally, psychological interventions are the most 
effective interventions for people with major depression. (89) The effectiveness of 
psychological interventions in these closely related conditions is promising for the 
psychological treatment of bipolar disorder, and effective psychological strategies for people 
with bipolar disorder could be clinically and economically important. 
 
Strengths and limitations  
Participants in our review are similar to those in ‘real world’ practice in several ways.  
For example, the proportion of men and women, and of people with bipolar type 1 and 
bipolar type 2 in the included studies were comparable to epidemiological samples. (4, 5) 
Most studies recruited participants from outpatient or community type setting, where these 
psychological interventions could be carried out. Few studies were undertaken outside of 
Europe and North America, and the effects of psychological interventions might differ in 
places with different healthcare systems and different levels community support.  
Although the evidence provides support for the use of psychological interventions in 
the treatment of people with bipolar disorder, our meta-analysis includes a number of trials 
with participants in different phases, sometimes euthymic, sometimes depressive, sometimes 
a mixture of both, and sometimes a mixture of depressive and manic. Most of the trials with 
participants in different phases of the illness did not report disaggregated data for people in 
the euthymic and the depressive phases, or for people who were depressed and people who 
were manic at the start of the trial. This is likely to lead to underestimating the effects on 
symptoms; people who are euthymic are without symptoms, thereby diluting the mean impact 
of psychological intervention on depressive and manic symptoms in these mixed populations. 
Similarly, where data on relapse includes trials in which participants were manic, this may 
have led to underestimating the impact on relapse rates; people who are manic are often 
difficult to engage in any psychological treatment, thereby diluting the effects of 
psychological therapy on relapse rates for those who are euthymic or depressed. In addition, 
the lack of disaggregated data on outcomes for people with mania makes it impossible to 
identify any possible harms or benefits of psychological therapies for this group. Finally, a 
limitation of including participants at different phases of illness is that we are not comparing 
like with like. Although statistical heterogeneity was minimal, summary effects should be 
interpreted with some caution in light of the clinical differences among participants across 
trials and also for therapeutic variations between interventions. 
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A further potential limitation of this analysis is the quality of the data. In some 
comparisons, evidence for different outcomes was not consistent. For example, a 
psychological intervention may appear to reduce symptoms but have no effect on treatment 
response.  Some trials were not registered, and there was evidence of selective reporting of 
outcomes, which could lead us to overestimate the benefits of psychological treatments in 
much the same way as selective publishing of drug studies has led to overestimating their true 
effectiveness. (90) Using GRADE to evaluate the quality of evidence underpinning each 
outcome, we incorporated these limitations in our evaluation of the results and restricted our 
conclusions to outcomes based on low and moderate quality evidence; importantly, evidence 
for key outcomes—relapse rates and symptoms—was better than evidence for most 
secondary outcomes. 
Almost all reviewed psychotherapies were given as adjuncts to pharmacotherapy 
(monotherapy or combinations of various medications), and they were delivered in a variety 
of different treatment modalities and service settings. Co-interventions and details about 
service settings were incompletely described in many trials and could contribute to 
unobserved heterogeneity. In addition, while there is a consensus that psychological 
treatments for bipolar disorder share many common elements and strategies (e.g. coping 
strategies for mood changes), they nevertheless differ in complexity, the skill and training 
required, content and duration, even when they bear the same name (e.g. cognitive 
behavioural therapy or psycho-education).  These problems may be addressed in further 
research in this rapidly expanding field.  
 
Implications for practice  
On the basis of this review, individual psychological interventions should be offered 
(in addition to whatever pharmacological interventions people already receive) with the aim 
of reducing relapse rates for people with bipolar disorder who are depressed or euthymic and 
for improving symptoms in people who are depressed. Although the evidence was limited for 
many outcomes in this review, there is strong evidence for the effectiveness of psychological 
interventions for unipolar depression (89) adding some support to the view that bipolar 
depression may be treated effectively with psychological treatment.  It is also worth 
considering family psychological interventions, not just because the trials show some 
promise, but also because the benefits of family interventions for psychosis (including 
schizophrenia and bipolar disorder) suggest that relapse rates can be reduced for early 
psychosis (87) and later psychosis. (88) It seems likely, on the basis of this broader evidence 
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as well as the evidence in this review, that family interventions could be beneficial for people 
with bipolar disorder and should be made available routinely to help reduce relapse rates.  
People with bipolar disorder may also benefit from group psycho-education and from 
collaborative care. It is important to keep in mind that people with bipolar disorder are often 
only partially adherent to pharmacotherapy, which may contribute to the recurrence of 
symptoms and to relapse. (91) Group or family psycho-educational interventions and 
collaborative care could help the people develop skills related to medication use, stress 
management, recognising early symptoms, and coping with symptoms. Such skills could  
reduce risk of relapse and improve response.  
Worldwide there are few people with training and experience of delivering specific 
psychological interventions for people with bipolar depression.  However, there are many 
therapists providing evidence-based treatments for unipolar depression in primary care.  
Because the rationale and process of delivering CBT for unipolar and bipolar depression is 
very similar, it might be sensible for CBT therapists in primary care to provide individual 
CBT for people with bipolar depression if they have experience in managing people with 
bipolar disorder or are supervised by clinicians with that experience. Many of the skills 
learned through CBT for depression could also help people with bipolar disorder who are 
euthymic avoid relapse. In the long-term, service providers and educational institutions 
should endeavour to increase the number of therapists trained specifically in the treatment of 
bipolar depression and the prevention of bipolar relapse.   
 
Directions for future research 
While this review supports the use of individual psychological intervention for relapse 
reduction and symptom improvement, we do not have sufficient information to know the 
impact on functioning and quality of life, both key concerns for people with bipolar disorder. 
Further research should include sufficiently large populations to address these critical 
outcomes. The same is true for family interventions.  Longer follow-up is needed to establish 
how well the effects of all of these interventions endure. Further research is needed to 
understand how psychological interventions compare with each other at each phase of the 
illness.  
Future studies could be improved by reporting results separately for people in different 
phases of the disorder (who are at risk of different outcomes), better describing treatments 
and comparators, pre-registering trials, completely and transparently reporting all outcomes 
measured, and standardising the use of outcome measurement. Moreover, including an 
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economic (cost-benefit) analysis in trials, especially when there is a possible reduction in 
relapse, would add greatly to our understanding of what we can do to help people with 
bipolar disorder; comparing the cost-effectiveness of individual and group approaches would 
address common concerns about method of delivery.   
There is very little, if any, evidence about which psychological treatments could be 
beneficial for people with more severe forms of bipolar disorder. More research could 
address the treatment of people who have very frequent episodes, people who are most 
severely functionally disabled, and people with persisting inter-episode symptoms. People 
who are hospitalized because of manic symptoms usually receive pharmacotherapy and we 
have identified no trial that examines whether a psychological intervention would be 
beneficial during this phase of the illness. Following this review, further research can be 
developed on the basis of much stronger evidence than was available only a few years ago.  It 
is clear that psychological interventions now have an important place alongside medication 
treatments in the treatment of people with bipolar disorder, and future research will elucidate 
the most effective ways to deliver psychotherapy.  
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Appendix 1 Systematic search 
The search was constructed using the groups of terms set out in Text Box 1. The full set of search terms is documented in sections 1 and 2. The 
selection of search terms was kept broad to maximise retrieval of evidence. 
Box 1 Summary of systematic search strategie: search strategy construction 
Box 1 Summary of systematic search strategie: search strategy construction 
Review area Search type Search construction Study design Databases searched and date range 
searched 
Psychosocial 
interventions 
for adults  
 
Generic 
search  
 
General medical 
databases: [(1 
population terms) 
AND (RCT terms/ 
SR terms)]  
 
Topic specific 
databases: 
[(population terms)]  
Qualitative 
systematic 
reviews, 
Randomised 
controlled 
studies  
 
General medical databases: (From 
inception to 20
th
 of January 2014) 
 
CINAHL (1961-2014), Embase (1947-
2014), MEDLINE (1966-2014), 
PreMEDLINE (1966-2014) and PsycINFO 
(1880-2014)  
 
Topic specific databases (From inception 
to 20th of January 2015): CDSR (1992-
2014), DARE (1968-2014), HMIC (1980-
2014), HTA (1995-2014) and  CENTRAL 
(1898-2014) 
 
 
1 Population search terms – all databases  
1.1 STEM – General medical databases  
Embase, MEDLINE, PreMEDLINE, PsycINFO – OVID SP  
 
1 exp bipolar disorder/ or mania/  
2 1 use emez  
3 exp bipolar disorder/  
4 3 use mesz, prem  
5 exp bipolar disorder/ or exp mania/  
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6 5 use psyh  
7 ((bi?polar adj5 (disorder$ or depress$)) or ((cyclothymi$ or rapid or ultradian) adj5 cycl$) or hypomani$ or mania$ or manic$ or mixed 
episode$ or rcbd).ti,ab.  
8 or/2,4,6-7  
 
1.2 STEM – topic specific databases 
HTA, CDSR, DARE, CENTRAL – Wiley 
#1 
mesh descriptor bipolar disorder explode all trees 
#2 
(((bipolar or “bi polar”) near/5 (disorder* or depress*)) or ((cyclothymi* or rapid or ultradian) near/5 cycl*) or hypomani* or mania* or 
manic* or “mixed episode*” or rcbd):ti,ab,kw 
#3 
(#1 or #2) 
 
1.3 STEM – topic specific databases  
CENTRAL – Wiley #1 mesh descriptor bipolar disorder explode all trees  
#2 (((bipolar or “bi polar”) near/5 (disorder* or depress*)) or ((cyclothymi* or rapid or ultradian) near/5 cycl*) or hypomani* or mania* or 
manic* or “mixed episode*” or rcbd):ti,ab,kw  
#3 (#1 or #2) 
 
1.4 STEM – topic specific databases  
CINAHL – Ebsco  
s3  s1 or s2  
s2  ti ( (((bipolar or “bi polar”) n5 (disorder* or depress*)) or ((cyclothymi* or rapid or ultradian) n5 cycl*) or hypomani* or mania* or 
manic* or “mixed episode*” or rcbd) ) or ab ( (((bipolar or “bi polar”) n5 (disorder* or depress*)) or ((cyclothymi* or rapid or ultradian) n5 
cycl*) or hypomani* or mania* or manic* or “mixed episode*” or rcbd) )  
s1  (mh "bipolar disorder")  
21 
 
 
1.5 STEM – topic specific databases 
HMIC – HDAS 
1 hmic bipolar disorder/ 
2 hmic (((bipolar or "bi polar") and (disorder* or depress*)) or ((cyclothymi* or rapid or ultradian) and cycl*) or hypomani* or mania* or 
manic* or "mixed episode*" or rcbd).ti,ab 
3 hmic 1 or 2 
 
2. Study design filters – all databases 
2.1 Quantitative systematic review study design filters 
2.1.1 Quantitative systematic review study design filter, general medical databases 
Embase, MEDLINE, MEDLINE In-Process, PsycINFO – OVID SP 
1 meta analysis/ or systematic review/ 
2 1 use emez 
3 meta analysis.sh,pt. or "meta-analysis as topic"/ or "review literature as topic"/ 
4 3 use mesz, prem 
5 (literature review or meta analysis).sh,id,md. or systematic review.id,md. 
6 5 use psyh 
7 (exp bibliographic database/ or (((electronic or computer$ or online) adj database$) or bids or cochrane or embase or index medicus or isi 
citation or medline or psyclit or psychlit or scisearch or science citation or (web adj2 science)).ti,ab.) and (review$.ti,ab,sh,pt. or 
systematic$.ti,ab.) 
8 7 use emez 
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9 (exp databases, bibliographic/ or (((electronic or computer$ or online) adj database$) or bids or cochrane or embase or index medicus or isi 
citation or medline or psyclit or psychlit or scisearch or science citation or (web adj2 science)).ti,ab.) and (review$.ti,ab,sh,pt. or 
systematic$.ti,ab.) 
10 9 use mesz, prem 
11 (computer searching.sh,id. or (((electronic or computer$ or online) adj database$) or bids or cochrane or embase or index medicus or isi 
citation or medline or psyclit or psychlit or scisearch or science citation or (web adj2 science)).ti,ab.) and (review$.ti,ab,pt. or 
systematic$.ti,ab.) 
12 11 use psyh 
13 ((analy$ or assessment$ or evidence$ or methodol$ or quantitativ$ or systematic$) adj2 (overview$ or review$)).tw. or ((analy$ or 
assessment$ or evidence$ or methodol$ or quantitativ$ or systematic$).ti. and review$.ti,pt.) or (systematic$ adj2 search$).ti,ab. 
14 (metaanal$ or meta anal$).ti,ab. 
15 (research adj (review$ or integration)).ti,ab. 
16 reference list$.ab. 
17 bibliograph$.ab. 
18 published studies.ab. 
19 relevant journals.ab. 
20 selection criteria.ab. 
21 (data adj (extraction or synthesis)).ab. 
22 (handsearch$ or ((hand or manual) adj search$)).ti,ab. 
23 (mantel haenszel or peto or dersimonian or der simonian).ti,ab. 
24 (fixed effect$ or random effect$).ti,ab. 
25 ((pool$ or combined or combining) adj2 (data or trials or studies or results)).ti,ab. 
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26 or/2,4,6,8,10,12-25 
 
2.1.2 Qualitative systematic review study design filter, topic specific databases 
CINAHL – EBSCO HOST 
s33 s1 or s2 or s3 or s4 or s5 or s6 or s7 or s8 or s9 or s10 or s11 or s12 or s13 or s14 or s15 or s16 or s22 or s23 or s26 or s27 or s28 or s29 or 
s30 or s31 or s32 
s32 ti ( analy* n5 review* or assessment* n5 review* or evidence* n5 review* or methodol* n5 review* or quantativ* n5 review* or 
systematic* n5 review* ) or ab ( analy* n5 review* or assessment* n5 review* or evidence* n5 review* or methodol* n5 review* or 
quantativ* n5 review* or systematic* n5 review* ) 
s31 ti ( analy* n5 overview* or assessment* n5 overview* or evidence* n5 overview* or methodol* n5 overview* or quantativ* n5 
overview* or systematic* n5 overview* ) or ab ( analy* n5 overview* or assessment* n5 overview* or evidence* n5 overview* or methodol* 
n5 overview* or quantativ* n5 overview* or systematic* n5 overview* ) 
s30 ti ( pool* n2 results or combined n2 results or combining n2 results ) or ab ( pool* n2 results or combined n2 results or combining n2 
results ) 
s29 ti ( pool* n2 studies or combined n2 studies or combining n2 studies ) or ab ( pool* n2 studies or combined n2 studies or combining n2 
studies ) 
s28 ti ( pool* n2 trials or combined n2 trials or combining n2 trials ) or ab ( pool* n2 trials or combined n2 trials or combining n2 trials ) 
s27 ti ( pool* n2 data or combined n2 data or combining n2 data ) or ab ( pool* n2 data or combined n2 data or combining n2 data ) 
s26 s24 and s25 
s25 ti review* or pt review* 
s24 ti analy* or assessment* or evidence* or methodol* or quantativ* or systematic* 
s23 ti “systematic* n5 search*” or ab “systematic* n5 search*” 
24 
 
s22 (s17 or s18 or s19) and (s20 or s21) 
s21 ti systematic* or ab systematic* 
s20 tx review* or mw review* or pt review* 
s19 (mh "cochrane library") 
s18 ti ( bids or cochrane or index medicus or “isi citation” or psyclit or psychlit or scisearch or “science citation” or web n2 science ) or ab ( 
bids or cochrane or index medicus or “isi citation” or psyclit or psychlit or scisearch or “science citation” or web n2 science ) 
s17 ti ( “electronic database*” or “bibliographic database*” or “computeri?ed database*” or “online database*” ) or ab ( “electronic 
database*” or “bibliographic database*” or “computeri?ed database*” or “online database*” ) 
s16 (mh "literature review") 
s15 pt systematic* or pt meta* 
s14 ti ( “fixed effect*” or “random effect*” ) or ab ( “fixed effect*” or “random effect*” ) 
s13 ti ( “mantel haenszel” or peto or dersimonian or “der simonian” ) or ab ( “mantel haenszel” or peto or dersimonian or “der simonian” ) 
s12 ti ( handsearch* or "hand search*" or "manual search*" ) or ab ( handsearch* or "hand search*" or "manual search*" ) 
s11 ab "data extraction" or "data synthesis" 
s10 ab "selection criteria" 
s9 ab "relevant journals" 
s8 ab "published studies" 
s7 ab bibliograph* 
s6 ab "reference list*" 
s5 ti ( “research review*” or “research integration” ) or ab ( “research review*”or “research integration” ) 
s4 ti ( metaanal* or “meta anal*”) or ab ( metaanal* or “meta anal*”) 
s3 (mh "meta analysis") 
25 
 
s2 (mh "systematic review") 
s1 (mh "literature searching+") 
 
 
2.2 Randomised controlled trial filters  
2.2.1 Randomized controlled trial study design filter, general medical databases  
Embase, MEDLINE, PreMEDLINE, PsycINFO – OVID SP 1  exp "clinical trial (topic)"/ or exp clinical trial/ or crossover procedure/ or 
double blind procedure/ or placebo/ or randomization/ or random sample/ or single blind procedure/  
2  1 use emez  
3  exp clinical trial/ or exp “clinical trials as topic”/ or cross-over studies/ or double-blind method/ or placebos/ or random allocation/ or 
single-blind method/  
4  3 use mesz, prem  
5  (clinical trials or placebo or random sampling).sh,id.  
6  5 use psyh  
7  (clinical adj2 trial$).ti,ab.  
8  (crossover or cross over).ti,ab.  
9  (((single$ or doubl$ or trebl$ or tripl$) adj2 blind$) or mask$ or dummy or doubleblind$ or singleblind$ or trebleblind$ or 
tripleblind$).ti,ab.  
10  (placebo$ or random$).ti,ab.  
11  treatment outcome$.md. use psyh  
12  animals/ not human$.mp. use emez  
13  animal$/ not human$/ use mesz, prem  
14  (animal not human).po. use psyh  
26 
 
15  (or/2,4,6-11) not (or/12-14) 
 
2.2.2 Randomized controlled trial study design filter, topic specific databases 
CINAHL– EBSCO Host 
s10 s9 not s8 
s9 s1 or s2 or s3 or s4 or s5 or s6 or s7 
s8 (mh "animals") not (mh "human") 
s7 (pt "clinical trial") or (pt "randomized controlled trial") 
s6 ti ( placebo* or random* ) or ab ( placebo* or random* ) 
s5 ti ( single blind* or double blind* or treble blind* or mask* or dummy* or singleblind* or doubleblind* or trebleblind* ) or ab ( single blind* 
or double blind* or treble blind* or mask* or dummy* or singleblind* or doubleblind* or trebleblind* ) 
s4 ti ( crossover or cross over ) or ab ( crossover or cross over ) 
s3 ti clinical n2 trial* or ab clinical n2 trial* 
s2 (mh "crossover design") or (mh "placebos") or (mh "random assignment") or (mh "random sample") 
s1 (mh "clinical trials+") 
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Figure 1 PRISMA Flow Diagram (21) 
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Table 1 Characteristics of the included studies 
STUDY Coun
try 
Mean 
Age  
 
% 
Fem
ale 
% 
Bipolar 
I 
Mood 
at 
baseline 
Intervention N 
Total 
or per 
arm 
Drop-out  
Total or 
per arm 
Hours 
of 
contact 
Duration 
(weeks) 
Follow-up 
(weeks) 
Individual Cognitive therapy (CT) / Cognitive Behavioural therapy (CBT) 
BALL2006 (64) AUS 42 58% NR M CT v TAU 25, 27 16% 20 26 52 / 78 
JONES2014 (33) GB 39 70% 79% M CBT  v TAU 33, 34 3% 18 26 52  
LAM2000 (66) GB 39 52% 100% M CBT  v TAU 13, 12 8% NR 26 52 
LAM2003 (67) GB 44 56% 100% M CT v TAU 51, 52 16% 16 26 52 
MEYER2012 (85) DE 44 50% 79% M CBT v Supportive therapy 38, 38 13%, 16% 18, 18 39 143 
MIKLOWITZ2007 (41) US 40 59% 67% Ad CBT v Collaborative therapy 75, 130 41%, 30% 11, 2 39, 6 52 
SCHMITZ2002 (44) US 34 52% NR Ad CBT  v TAU 25, 21 36%, 67% 20 12 - 
SCOTT2001 (50) GB 39 60% 81% A and  
M 
CT v TAU 21, 21 14% 11 26 - 
SCOTT2006 (51) GB 41 65% 94% A and  
M 
CBT  v TAU 127, 
126 
17% NR 26 72 
ZARETSKY2008 (65) CA 41 NR 66% M CBT  v TAU 40, 39 28% NR 13 52 
Psychological therapy for medication adherence  (PTM)        
COCHRAN1984 (68) US 33 61% 75% M PTM v TAU 14, 14 14% 6 6 32 
EKER2012 (40) TR 36 54% NR M PTM vs Attention control 35, 36 17% 12 6 - 
Individual Psychoeducation (PE)          
JAVADPOUR2013 
(61) 
IR NR 51% NR M PE v TAU 54, 54 17%, 24% 7 8 26 / 52 / 78 
LOBBAN2010 (62) GB 45 68% 98% M PE v TAU 56, 40 5% 6 6 48 
PERRY1999 (63) GB 45 68% 91% M PE v TAU 34, 36 21% 9 NR 52 
DOGAN2003 (60) TR 37 35% NR M PE v TAU 14, 12 NR 14 6 - 
 Individual PE vs  Group Cognitive Behavioural therapy (CBT)      
PARIKH2012 (37) CA 41 58% 72% M PE vs CBT 95, 109 34%, 36% 17, 9 20, 6 72 
Online Psychoeducation (PE)           
PROUDFOOT2012 
(58) 
AUS NR 70% NR Ad and 
M 
PE vs Attention control 139, 
141 
32%, 29% 0 8 26 
SMITH2011 (59) GB 44 62% 86% M PE vs TAU 24, 26 33% NR 17 43 
TODD 2014 (49) GB 43 72% NR A and 
M 
PE vs TAU 61, 61 66% 0 26 - 
Group Cognitive Behavioural therapy (CBT)        
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STUDY Coun
try 
Mean 
Age  
 
% 
Fem
ale 
% 
Bipolar 
I 
Mood 
at 
baseline 
Intervention N 
Total 
or per 
arm 
Drop-out  
Total or 
per arm 
Hours 
of 
contact 
Duration 
(weeks) 
Follow-up 
(weeks) 
DEBARROS2013 (34) BR 44 69% NR M CBT v  Attention control 32, 23 NR 24 8 34 / 60 
BERNHARD2009 (31) DE 39 73% 63% M CBT v TAU 32, 36 22% 18 12 52 
GOMES2011 (73) BR 38 76% 76% M CBT v TAU 23, 27 0% 27 26 78 
COSTA2012 (74) BR 40 62% 84% M CBT v TAU 27, 14 0% 28 14 40 
Group Social cognition and interaction training        
LAHERA2013 (77) ES 39 65% 76% M CBT v TAU 21, 16 19% 18 18 - 
Group Mindfulness based cognitive therapy         
WILLIAMS2008 (76) GB NR NR NR M Mindfulness v Wait list 9, 8 NR 23 8 - 
PERICH2013 (75) AUS NR 65% 62% M Mindfulness v TAU 48, 47 21%, 38% 18 8 22/ 
35/48/61 
Group Dialectical Behaviour Therapy (DBT)         
VAN DIJK2013 (42) CA 42 75% 42% Ad DBT v TAU 13, 13 8%, 8% 18 12 - 
Functional remediation           
TORRENT2013 (71) ES  40 NR NR M Functional remediation v TAU 77, 80 29%, 18% 32 21 47 
Group Psychoeducation (PE)           
SAJATOVIC2009 (47) US 41 68% NR A PE v TAU 84, 80 51% NR 52 - 
CASTLE2010 (72) AUS 42 77% 74% M PE v TAU 42, 42 24% 23 13 52 
TORRENT2013 (71) ES 40 NR NR M PE v TAU 82, 80 24%, 18% 32 21 47 
COLOM2003 (69) ES 35 62% 100% M PE v Attention control 25, 25 NR 32 20 124 
COLOM2003 ((70) ES 34 63% 83% M PE v Attention control 60, 60 27% 32 21 124 
Family psychoeducation (Service users and carers)        
CLARKIN1998 (36) US 48 46% 100% A Family PE v TAU 19, 23 5%, 35% NR 48 - 
D'SOUZA2010 (78) AUS 40 52% 86% M Family PE v TAU 27, 31 NR 18 12 60 
GLICK1993 (35) US 32 67% NR A Family PE v TAU   15, 11 20%, 19% 8 7 33 
MILLER2004 (48) US 39 56% 100% A Family PE v TAU 33, 29 36% 10 NR 121 
Family psychoeducation (Carers)          
BORDBAR2009 (79) 
 
IR 30 22% 100% M Family PE v TAU 29, 28 0% 2 1 52 
VAN GENT1991 (82) NL 49 NR NR M Family PE v Waitlist 14, 12 0% NR 5 31 
MADIGAN2012 (80) IE 42 65% NP M Family PE v Short carer focused 
intervention v TAU 
18, 19, 
10 
28%, 
21% 
NR 5 
 
57 / 109 
PERLICK2010 (56) US 35 62% 87% A and  
M 
Short carer focused intervention 
v TAU 
25, 21 4%, 10% 11 14 - 
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STUDY Coun
try 
Mean 
Age  
 
% 
Fem
ale 
% 
Bipolar 
I 
Mood 
at 
baseline 
Intervention N 
Total 
or per 
arm 
Drop-out  
Total or 
per arm 
Hours 
of 
contact 
Duration 
(weeks) 
Follow-up 
(weeks) 
REINARES2008 (81) ES 34 54% 83% M Family PE v TAU 57, 56 5% 18 12 65 
Family Focused Therapy (FFT)          
MIKLOWITZ2000 (55) US 36 63% 100% A and  
M 
FFT v TAU 31, 70 10% 21 39 52 / 104 
MIKLOWITZ2007 (41) US 40 59% 67% Ad FFT v Collaborative therapy 26, 130 27%, 30% 11, 2 39, 6 52 
MILLER2004 (48)  US 39 56% 100% A FFT vTAU 30, 29 36%, 33% 10, 9 NR 121 
REA2003 (84) US 26 NR 100% M FFT v PE (Individual) 28, 25 21%, 2% 21, 11 39, 39 - 
Interpersonal and social rhythm therapy (IPSRT)        
SWARTZ2012 (43) US 37 60% 0% Ad IPRST v Quetiapine 14, 11 21%, 38% 6 12 - 
FRANK1999 (46) US 35 56 100% A IPRST v 
Intensive clinical management 
39 
43 
43% 
37% 
38 
15 
123 
 
- 
MIKLOWITZ2007 (41) US 40 59% 67% Ad IPRST vs TAU 62, 130 32%, 30% 14, 2 39, 6 52 
Collaborative care (Psychiatric focus)         
BAUER2006 (45) US 47 9% 87% A Collaborative care v TAU 166, 
164 
25%, 15% NR 156 - 
SIMON2005 (54) US 44 69% 76% A and  
M 
Systematic care management 
program v TAU 
212  
229 
NR NR 52 - 
KESSING2013 (83) DK 36 54% NR M Specialized outpatient mood 
disorder clinic v TAU 
72,  
86 
0%,  
0% 
NR 
NR 
104/130 
104/130 
- 
Collaborative care (Physical health focus)         
FAGIOLINI2009 (38) US 41 61% 67% A and  
M 
Enhanced Clinical Intervention 
vs TAU 
235, 
228 
NR NR 85 - 
KILBOURNE2008 (52) US 55 9% 76% A and  
M 
Collaborative care v TAU 61 NR NR 26 - 
KILBOURNE2012 (53) US 45 61% NR A and  
M 
Collaborative care v TAU 34, 34 NR NR 30 52 
Integrated group therapy (IGT)          
WEISS2007 (39) US 42 52% 81% Ad and 
M 
IGT v Drug counselling 31,31 23%, 45% 20, 20 20, 20 35 
WEISS2009 (57) US 38 41% 79% Ad and 
M 
IGT v Drug counselling 31, 30 19%, 20% 12, 12 12, 12 26 
Integrated Cognitive and Interpersonal Therapy (IC&IT)        
SCHWANNAUER2007 GB 37 48% 95% NR IC&IT v TAU 212 23%, 17% 25 20 46, 98 
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STUDY Coun
try 
Mean 
Age  
 
% 
Fem
ale 
% 
Bipolar 
I 
Mood 
at 
baseline 
Intervention N 
Total 
or per 
arm 
Drop-out  
Total or 
per arm 
Hours 
of 
contact 
Duration 
(weeks) 
Follow-up 
(weeks) 
(32) 
 
Definitions of abbreviations 
TAU = Treatment as usual; PE = Psychoeducation; NR = Not reported;  
M = maintenance (participants euthymic at baseline);  Ad = participants in an acute depression at baseline; A =   participants in an acute episode of mania or depression; 
AUS = Australia;  BR =  Brazil; CA =  Canada;  DE =  Germany; DK =  Denmark; ES =  Spain;  GB =  United Kingdom; IE =  Ireland; IR =   Islamic Republic of  Iran;   
NL =  Netherlands;  TR =  Turkey;   US = United States; 
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Table 2 Defining characteristics of psychological interventions* and collaborative care 
Intervention Mean/range 
contact 
(hours) 
Mean/range 
group size 
Mean/range 
duration 
(weeks) 
Key elements 
First comparison  
Individual Cognitive therapy (CT) /  
Cognitive Behavioural therapy (CBT) 
16 (11-20) N/A 28 (12-39) Psychoeducation, identifying and modifying dysfunctional and negative thoughts, 
underlying maladaptive assumptions and beliefs, problem-solving training and 
strategies for early detection of mood episodes. 
Psychological therapy for medication 
adherence  (PTM) 
9 (6-12) N/A 6 Modified cognitive-behavioural intervention aimed at altering cognitions and 
behaviours that interfere with compliance.  Psychoeducation, monitoring, and then 
instructions to alter compliance behaviour. 
Individual Psychoeducation (PE) 9 (6-11) N/A 17 (6-39) Education on bipolar disorder, causative factors, clinical symptoms and early warning 
signs, medication side effects, and coping strategies for mood changes. Most PE 
interventions include the creation of a (relapse prevention) action plan. 
Online Psychoeducation (PE) 0 N/A 15 (8-26) Online interactive program addressing topics such as the causes of bipolar disorder, 
diagnosis, treatments,  role of lifestyle (changes) and the importance of support.  
Functional remediation 32 NR 21 Psychoeducation on cognitive deficits and their impact on daily life, strategies to 
manage them , especially attention, memory and executive function, with a special 
focus on enhancement of functioning in daily routine 
Second comparison 
Group Cognitive Behavioural 
therapy (CBT) 
 
24 (18-28) 6 17 (12-26) Psychoeducation, identifying and modifying dysfunctional and negative thoughts, 
underlying maladaptive assumptions and beliefs, problem-solving training and 
strategies for early detection of mood episodes. 
Group Social cognition and 
interaction training 
18 12 18 Emotional training (definition of emotions, facial expression training, understanding of 
paranoid symptoms as an emotion); role-play social situations (distinguishing facts 
from guesses, jumping to conclusions, understanding bad events); and integration of 
learning. 
Group Mindfulness based cognitive 
therapy 
21 (18-23) 10 (6-14) 8 Psychoeducation, mindfulness meditation (observations of thoughts, feelings and 
bodily reactions) practice and cognitive therapy regarding depression.  
Group Dialectical Behaviour 
Therapy (DBT) 
18 N/A 12 Psychoeducation about bipolar disorder and treatment. Training of skills: states of 
mind, reducing vulnerability to emotions, non judgmental stance, acceptance, 
distracting, self-soothing, pro’s and con’s, urge management, self-validation opposite 
to emotion action and balancing enjoyable activities with responsibilities. 
Group Psychoeducation (PE) 25 (9-32) 9 (7-10) 22 (8-26) Interactive group sessions covering illness and treatment education, symptom 
monitoring and early detection, treatment adherence, illness management skills, coping 
strategies and problem solving.  
Third  comparison 
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Family psychoeducation (Service user 
and carers) 
12 (9-18) N/A 22 (7-48) Intervention for family and the service user.  Psychoeducation on bipolar and 
treatment, enhancing relationships (spouse, family, clinician), problem focused coping 
strategies. 
Family psychoeducation (Carers) 10 (2-18) N/A 6 (1-12) Intervention for the family only. Psychoeducation on bipolar and treatment, dealing 
with one's own functioning (stress and other health risks) and practical advice.  
Fourth  comparison 
Collaborative care (Psychiatric focus) N/A N/A N/A Psychoeducation and a review of symptoms and side effects, medical and behavioural 
management of side effects, discussion of early-warning signs of impending episodes, 
and a (24-hour on-call) coordinating team of health professionals.  
Collaborative care (Physical health 
focus) 
N/A N/A N/A Self-management, psychoeducation, disease (cardiovascular) prevention strategies and 
a care manager/team who advocates the service users interests.  
Fifth  comparison 
Integrated Cognitive and 
Interpersonal Therapy 
25 8 20 Individuals could choose the group or individual intervention. Psychoeducation, 
identification of  early warning signs, behavioural strategies for coping with 
symptoms, cognitive strategies, affect regulation techniques, social network analysis, 
and identification of interpersonal patterns and strategies. 
Sixth  comparison 
Family Focused Therapy (FFT) 15 (10-21) N/A 39  An intervention with the service user and his/her family. Psychoeducation about 
bipolar disorder, communication enhancement training, and problem-solving skills 
training. 
Seventh  comparison (See Individual Cognitive Behavioural therapy (CBT) for  characteristics) 
Eight  comparison 
Interpersonal and social rhythm 
therapy (IPSRT) 
16 (6-38) N/A 12 (19-39) Based on interpersonal therapy, but focussing on stabilizing social rhythms  (social 
routines, daily activities and sleep/wake cycles) trough monitoring and anticipating on 
disruptive events.  
Ninth  comparison 
Integrated group therapy (IGT) 16 (12-20) 5 16 (12-20) Cognitive behavioural relapse prevention model focusing on similarities between 
recovery/relapse processes in bipolar disorder and substance use disorder. 
Drug counselling 16 (12-20) 5 16 (12-20) A treatment group to facilitate abstinence from drug misuse, encourage mutual 
support, and teach new ways to cope with substance-related problems. 
* Psychological interventions are structured interventions based on psychological models (linking thoughts, feelings and behaviour) of mood disorders. Main goals are to 
establish stable, normal mood and restore (social) functioning.  
N/A = not applicable 
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Table 3 Continuous measures used in included trials 
 
Outcome type Scales 
Symptoms of 
depression 
Bech–Rafaelsen Melancholia Scale (BRMS), Beck Depression Inventory (BDI), Center for Epidemiological Studies Depression Scale (CES-D), 
Goldberg Anxiety and Depression Scale (GADS), Hamilton Depression Rating Scale (HAM-D), Montgomery-Asberg Depression Rating Scale 
(MADRS), Bipolar Longitudinal Investigation of Problems (BLIP), Internal State Scale (ISS), Depression and Schedule for Affective Disorders and 
Schizophrenia, change version (SADS-C).   
Symptoms of mania 
symptoms 
Altman Self‐Rating‐Mania‐Scale, Bech-Rafaelsen Mania Scale (BRMS), Bipolar Longitudinal Investigation of Problems (BLIP), Mania Rating 
Scale (MAS), Schedule for Affective Disorders and Schizophrenia, change version (SADS-C), Self-Rating Mania Inventory (SRMI) and Young 
Mania Rating Scale (YMRS).  
Psychosocial 
functioning 
Global Assessment of Functioning (GAF), MRC Social Performance Schedule (SPS), Social Adaptation Self Evaluation Scale (SASS), different 
versions of Social Adjustment Scale (SAS), Social and Occupational Functioning Assessment Scale (SOFAS), Social Functioning Interview, Social 
Performance Schedule (SPS), UCLA Social Attainment Scale, Work and Social Adjustment Scale (WSAS) and World Health Organization 
Disability Assessment Scale (WHODAS). 
Quality of life Medical Outcomes Study 36-item Short Form Health Survey (MOS-SF-36), Satisfaction with Life Scale (SWLS), Quality of Life in BD scale 
(QoL.BD), World Health Organisation Quality of Life Instrument. 
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Table 4 Risk of Bias graph 
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Table 5 Risk of Bias summary 
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Table 5 (continues) Risk of Bias 
 
Caption: Risk of bias was rated as low (+), high (-), or  unclear (?) using the Cochrane Risk of Bias Tool (22).;  
M = maintenance (participants euthymic at baseline);  Ad = participants in an acute depression at baseline; A =   
participants in an acute episode of mania or depression;
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Table 6: Outcomes at post-treatment  
Outcome Number of studies (k) 
and participants (N) 
 
Effect size (95% CI) 
 
 
Heterogeneity:  
Chi² (p value); I² 
Intervention 
length (weeks) 
Quality 
(GRADE)(26) 
 
1. Individual psychological intervention1 versus treatment as usual (TAU)  
Depression symptoms k=8 ; N=683 SMD = -0.23 (-0.41, -0.05) 8.55 (P = 0.29); 18% 6-26 Low a e 
Mania symptoms k=3 ; N=171 SMD= -0.05 [-0.35, 0.25] 0.48 (P = 0.79); 0% 26 Very Low a d e 
Hospitalisation  k=1 ; N=28 RR = 0.14 (0.01, 2.53) N/A 6 Low d e 
Relapse (any) k=6 ; N=365 RR = 0.66 (0.48, 0.92) 2.50 (P = 0.78); 0% 6-26 Moderate d 
Response k=1 ; N=33 RR = 0.71 (0.46, 1.07) N/A 26 Very Low d e 
 
2. Group psychological intervention2 versus TAU 
Depression symptoms k=8 ; N=423 SMD = -0.24 (-0.64, 0.16) 25.65 (P = 0.0006); 73% 8-52 Very Low a b d 
e 
Mania symptoms k=6 ; N=375 SMD= -0.08 [-0.33, 0.16] 5.60 (P = 0.35); 11% 8-52 Very low a d e 
Hospitalisation  k=3 ; N=205 RR = 0.45 (0.10, 2.09) 3.94 (P = 0.14); 49% 14-21 Low d 
Relapse (any) k=2 ; N=170 RR = 0.48 (0.22, 1.04) 2.42 (P = 0.12); 59% 21 Low d 
Relapse (depression) k=2 ; N=170 RR = 0.39 (0.19, 0.78) 0.45 (P = 0.50); 0% 21 Low d 
Relapse (mania) k=2 ; N=170 RR = 0.48 (0.28, 0.82) 0.80 (P = 0.37); 0% 21 Low d 
 
3. Family psychoeducation versus TAU 
Depression symptoms k=1 ; N=43 SMD = -0.73 (-1.35, -0.10) N/A 14 Low d e 
Mania symptoms k=1 ; N=43 SMD=  -0.66 [-1.28, -0.04] N/A 14 Low d e 
 
4. Collaborative care versus TAU 
Depression symptoms k=2 ; N=123 SMD = -0.22 (-0.63, 0.19) 1.32 (P = 0.25); 24% 26-30 Low a d e 
Mania symptoms k=2 ; N=123 SMD=-0.07 [-0.47, 0.32] 1.24 (P = 0.27); 19% 26-30 Low a d e 
Hospitalisation  k=3 ; N=572 RR = 0.68 (0.49, 0.94) 0.13 (P = 0.72); 0% 52-130 Moderate d 
Relapse (any) k=1 ; N=414 RR = 0.99 (0.84, 1.17) N/A 52 Lowd e 
                                                 
1
 Cognitive behaviour therapy; (online) psychoeducation; medication adherence therapy. 
2
 Mindfulness based cognitive therapy; dialectical behaviour therapy; social cognition and interaction training, psychoeducation, cognitive behaviour therapy. 
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5. Integrated cognitive and interpersonal therapy versus TAU 
Depression symptoms k=1 ; N=193 SMD = -0.64 (-1.19, -0.09) N/A 20 Low d  
Mania symptoms k=1 ; N=193 SMD=  -0.10 [-0.30, 0.10] N/A 20 Low d e 
 
6. Family -focused therapy versus active control 
Depression symptoms k=1 ; N=79 SMD = -0.40 (-0.80, 0.00) N/A 39 Low a d  
Mania symptoms k=1 ; N=79 SMD=  0.00 [-0.40, 0.40] N/A 39 Low a d  
Relapse (any) k=1 ; N=53 RR = 0.89 (0.52, 1.54) N/A 39 Low d  
Hospitalisation  k=1 ; N=53 RR = 0.71 (0.33, 1.52) N/A 39 Low d 
 
7. CBT versus active control 
Depression symptoms k=1 ; N=76 SMD = 0.41 (0.12, 0.70) N/A 39 Low d e 
Mania symptoms k=1 ; N=76 SMD=0.20 [-0.11, 0.51] N/A 39 Low d e 
Relapse (any) k=1 ; N=76 RR = 0.60 (0.34, 1.05) N/A 39 Low d e  
 
8. Interpersonal and social rhythm therapy versus active control 
Depression symptoms k=1 ; N=25 SMD = 0.44 (-0.34, 1.22) N/A 12 Very Low a d 
Relapse (any) k=1 ; N=41 RR = 1.55 (0.63, 3.84) N/A 123 Very Low a d 
Response (any) k=1 ; N=25 RR = 0.98 (0.60, 1.60) N/A 12 Very Low a d 
 
9. Integrated group therapy versus active control 
Depression symptoms k=1 ; N=61 SMD = -0.35 (-0.85, 0.16) N/A 12 Very Low c d e 
Mania symptoms k=1 ; N=61 SMD= -0.17 [-0.68, 0.33] N/A 12 Very Low c d e  
a Risk of bias, b Inconsistency, c Indirectness, d Imprecision, e Publication/Reporting Bias); N/A = not applicable; SMD = Standardized Mean Difference; RR = Risk Ratio   
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Table 7: Outcomes at follow-up  
Outcome Number of studies (k) 
and participants (N) 
 
Effect size (95% CI) Heterogeneity: 
Chi² (p value); I² 
Follow-up 
period 
(weeks) 
Quality 
(GRADE)(26) 
 
1. Individual psychological intervention3 versus TAU 
Depression symptoms k=5 ; N=534 SMD = -0.21 (-0.43, 0.01) 6.85 (P = 0.23); 27% 26-52 Low a d  
Mania symptoms k=4 ; N=164 SMD=-0.38 [-0.71, -0.04] 3.40 (P = 0.33); 12% 52 Very Low a d e 
Hospitalisation  k=3 ; N=194 RR = 0.63 (0.38, 1.02) 2.19 (P = 0.35); 9% 32-52 Low d 
Relapse (any) k=8 ; N=532 RR = 0.74 (0.63, 0.87) 5.78 (P = 0.57); 0% 32-78 Moderate d 
Response k=1 ; N=52 RR = 0.46 (0.21, 1.02) N/A 52 Very Low a d e 
 
2. Group psychological intervention versus4 TAU 
Depression symptoms k=3 ; N=219 SMD = 0.22 (-0.05, 0.49) 0.95 (P = 0.62); 0% 52-61 Very Low a d e 
Mania symptoms k=3 ; N=219 SMD= 0.16 [-0.10, 0.43] 0.76 (P = 0.68); 0% 52-61 Very Low a d e 
Hospitalisation  k=3 ; N=200 RR = 0.48 (0.16, 1.45) 2.30 (P = 0.13); 56% 78-124 Very Low b d e 
Relapse (any) k=5 ; N=395 RR = 0.86 (0.61, 1.20) 21.46 (P = 0.0003); 81% 52-124 Very Low b d e 
Relapse (depression) k=5 ; N=333 RR = 0.62 (0.45, 0.88) 7.12 (P = 0.13); 44% 52-124 Low b d  
Relapse (mixed episode) k=4 ; N=274 RR = 0.48 (0.30, 0.77) 2.38 (P = 0.50); 0% 52-124 Low b d 
 
3. Family psychoeducation versus TAU 
Depression symptoms k=1 ; N=53 SMD = -0.15 (-0.69, 0.39) N/A 60 Very Low a d e 
Mania symptoms k=1 ; N=53 SMD=  -0.78 [-1.34, -0.22] N/A 60 Very Low a d e 
Hospitalisation  k=1 ; N=57 RR = 0.05 (0.00, 0.83) N/A 60 Low d  
Relapse (any) k=3 ; N=228 RR = 0.52 (0.32, 0.84) 2.61 (P = 0.27); 23% 52-65 Low d e 
Relapse (depression) k=1 ; N=113 RR = 0.73 (0.44, 1.21) N/A 65 Low d e 
Relapse (mania) k=1 ; N=113 RR = 0.35 (0.15, 0.85) N/A 65 Low d 
Response k=1 ; N=59 RR = 0.67 (0.34, 1.32) N/A 121 Very Low a d e 
 
4. Collaborative care versus TAU 
Depression symptoms k=1 ; N=65 SMD = -0.56 (-1.06, -0.07) N/A 52 Very Low a d 
                                                 
3
 Cognitive behaviour therapy; (online) psychoeducation; medication adherence therapy. 
4
 Mindfulness based cognitive therapy; psychoeducation, cognitive behaviour therapy. 
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Mania symptoms k=1 ; N=65 SMD= -0.10 [-0.59, 0.38] N/A 52 Very Low a d 
 
6. Family-focused therapy versus (active) control 
Depression symptoms k=1 ; N=79 SMD = -0.10 (-0.56, 0.36) N/A 52 Very Low a d e 
Mania symptoms k=1 ; N=79 SMD= -0.30 [-0.68, 0.08] N/A 52 Very Low a d  
Relapse (any) k=1 ; N=101 RR = 0.67 (0.34, 1.30) N/A 52 Very Low a d e 
Response (any) k=1 ; N=62 RR = 1.15 (0.68, 1.94) N/A 121 Very Low a d e 
Hospitalisation  k=1 ; N=38 RR = 0.24 (0.08, 0.74) N/A 104 Very Low a d 
 
7. CBT versus active control 
Depression symptoms k=1 ; N=76 SMD = 0.49 (0.04, 0.94) N/A 143 Very Low d e 
Relapse (any) k=1 ; N=76 RR = 1.13 (0.81, 1.58) N/A 143 Very Low d e 
 
8. Interpersonal and social rhythm therapy versus active control 
Response (depression)  k=1 ; N=192 RR = 0.73 (0.50, 1.07) N/A 52 Very Low a d e 
 
9. Integrated group therapy versus drug counselling (group) 
Depression symptoms k=1 ; N=61 SMD = 0.11 (-0.39, 0.61) N/A 26 Very Low c d e 
Mania symptoms k=1 ; N=61 SMD=  -0.53 [-1.05, -0.02] N/A 26 Very Low c d e 
a Risk of bias, b Inconsistency, c Indirectness, d Imprecision, e Publication/Reporting Bias) 
N/A = not applicable; SMD = Standardized Mean Difference; RR = Risk Ratio   
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Table 8 Outcomes at post-treatment 
 
 
1. Individual psychological intervention vs Treatment as usual (TAU) 
Outcome (Sub-)analysis Trials 
(reference) 
N ES [95% CI] Heterogeneity: Chi² (p 
value); I² 
Interv
ention 
length 
(weeks) 
Quality 
(GRADE)(26) 
Depression symptoms Total 8 683 SMD= -0.23 [-0.41, -0.05] 8.55 (P = 0.29); 18% 6-26 Low
 a e
 
 Online Psychoeducation (49, 58) 378 SMD= -0.18 [-0.63, 0.26] 3.88 (P = 0.05); 74% 6-26  
 CBT (33, 64, 66, 
67) 
305 SMD= -0.31 [-0.53, -0.08] 2.97 (P = 0.70); 0% 26  
Mania symptoms CBT (64, 66, 67) 171 SMD= -0.05 [-0.35, 0.25] 0.48 (P = 0.79); 0% 26 Very Low
 a d e
 
Hospitalisation  Medication adherence therapy (68) 28 RR= 0.14 [0.01, 2.53] N/A 6 Low
 d e
 
Relapse, any type  Total 6 365 RR= 0.66 [0.48, 0.92] 2.50 (P = 0.78); 0% 6-26 Moderate
 d
 
 Psychoeducation (63) 70 RR= 0.69 [0.41, 1.15] N/A 6  
 Medication adherence therapy (68) 28 RR= 0.40 [0.09, 1.73] N/A 6  
 CBT (50, 64, 65, 
67) 
267 RR= 0.67 [0.43, 1.04] 2.02 (P = 0.57); 0% 26  
Relapse, depression  Total 2 122 RR= 0.54 [0.06, 4.70] 4.15 (P = 0.04); 76% 6-26 Very Low
 a b d
 
 Psychoeducation (63) 70 RR= 1.29 [0.61, 2.73] N/A 6  
 CBT (64) 52 RR= 0.15 [0.02, 1.17] N/A 26  
Relapse, mania  Psychoeducation (63) 70 RR= 0.19 [0.05, 0.81] N/A 6 Very Low
 d e
 
Response, any  CBT (50) 33 RR= 0.71 [0.46, 1.07] N/A 26 Very Low
 d e
 
Quality of life Total 4 451 SMD= -0.46 [-1.05, 0.12] 20.14 (P = 0.0002); 85% 6-26 Very Low
 a b e
 
 Psychoeducation (60) 26 SMD= -0.36 [-1.30, 0.59] N/A 6  
 Online Psychoeducation (49, 58) 378 SMD= -0.86 [-1.26, -0.45] 16.50 (P < 0.0001); 94% 6-26  
 CBT (33) 47 SMD= -0.35 [-0.93, 0.23] N/A 26  
Psychosocial CBT (64) 94 SMD= -0.49 [-0.90, -0.08] 0.10 (P = 0.75); 0% 26 Very Low
 a d e
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functioning GAF 
Psychosocial 
functioning Social 
and/or Work 
Total 7 606 SMD= -0.34 [-0.51, -0.17] 
 
6.49 (P = 0.37); 8% 6-26 Low
 a  e
 
 Psychoeducation (33, 63) 70 SMD= -0.17 [-0.64, 0.30] N/A 6  
 Online Psychoeducation (49, 58) 378 SMD= -0.31 [-0.67, 0.05] 2.55 (P = 0.11); 61% 6-26  
 CBT (33, 50, 64, 
66) 
158 SMD= -0.55 [-0.87, -0.23] 1.20 (P = 0.75); 0% 26  
Study Discontinuation Total 9 755 RR= 0.74 [0.44, 1.27] 11.29 (P = 0.13); 38% 6-26 Low d e  
 Psychoeducation (62, 63) 166 RR=3.04 [0.33, 28.16] 1.28 (P = 0.26); 22% 6  
 Online Psychoeducation (49) 122 RR=1.13 [0.46, 2.72] N/A 26  
 Medication adherence therapy (68) 28 No dropout N/A 6  
 CBT (33, 50, 51, 
64, 66) 
439 RR= 0.58 [0.30, 1.13] 7.87 (P = 0.10); 49% 26  
 
2. Group psychological intervention vs Treatment as usual (TAU) 
 
Outcome (Sub-)analysis Trials 
(reference) 
N ES [95% CI] Heterogeneity: Chi² (p 
value); I² 
Inter
venti
on 
lengt
h 
(week
s) 
Quality 
(GRADE)(26) 
Depression symptoms Total 8 423 
 
SMD= -0.24 [-0.64, 0.16] 25.65 (P = 0.0006); 73% 8-52 Very   
Low
 a b d e
 
 Psychoeducation (47, 72) 152 SMD= 0.14 [-0.17, 0.46] 0.00 (P = 0.98); 0% 13-52  
 Mindfulness based cognitive 
therapy 
(75, 76) 109 SMD= -0.50 [-0.89, -0.12] 
 
0.20 (P = 0.65); 0% 
 
8  
44 
 
 Dialectical behaviour therapy (42) 24 SMD=-1.18 [-2.06, -0.30] N/A 12  
 CBT (31, 74) 91 SMD= -0.55 [-1.12, 0.02] 1.68 (P = 0.20); 40% 12-14  
 Social cognition and 
interaction training 
(77) 37 SMD= 0.92 [0.23, 1.61] 
 
N/A 18  
Mania symptoms Total 6 375 
 
SMD= -0.08 [-0.33, 0.16] 5.60 (P = 0.35); 11% 8-52 Very low a d e 
 Psychoeducation (47, 72) 152 SMD=0.06 [-1.05, 1.18] 1.69 (P = 0.19); 41% 13-52  
 Mindfulness based cognitive 
therapy 
(75) 95 SMD=-0.10 [-0.50, 0.30] N/A 8  
 CBT (31, 74) 91 SMD=-0.21 [-0.89, 0.47] 1.75 (P = 0.19); 43% 12-14  
 Social cognition and 
interaction training 
(77) 37 SMD= -0.37 [-1.02, 0.28] 
 
N/A 18  
Hospitalisation  Total 3 205 RR=0.45 [0.10, 2.09] 3.94 (P = 0.14); 49% 14-21 Low
 d
 
 PE vs attention control (69, 70) 170 RR=0.52 [0.06, 4.84] 2.48 (P = 0.12); 60% 21  
 CBT (74) 35 RR=0.20 [0.02, 1.97] N/A 14  
Relapse, any type  PE vs attention control (69, 70) 170 RR=0.48 [0.22, 1.04] 2.42 (P = 0.12); 59% 21 Low
 d
 
Relapse, depression  PE vs attention control (69, 70) 170 RR=0.39 [0.19, 0.78] 0.45  (P = 0.50); 0% 21 Low
 d
 
Relapse, mania  PE vs attention control (69, 70) 170 RR=0.48 [0.28, 0.82] 0.80  (P = 0.37); 0% 21 Low
 d
 
Relapse, mixed episode  PE vs attention control (69, 70) 170 RR=0.43 [0.18, 1.07] 1.11 (P = 0.29); 10% 21 Low
 d
 
Quality of life CBT (31, 74) 91 SMD=-0.38 [-1.74, 0.99] 9.06  (P = 0.003); 89% 12-14 Very Low
 a b d e
 
Psychosocial 
functioning GAF 
Total  2 89 SMD= 0.01 [-0.40, 0.43] 
 
0.01 (P = 0.92); 0% 12-18 Very Low
 a d e
 
 CBT (31) 52 SMD=0.03 [-0.51, 0.58] N/A 12  
 Social cognition and 
interaction training 
(77) 37 SMD=-0.01 [-0.66, 0.64] 
 
N/A 18  
Psychosocial 
functioning Social 
and/or Work 
Social cognition and 
interaction training 
(77) 37 SMD=0.43 [-0.23, 1.09] 
 
N/A 18 Very Low
 a d e
 
Study Discontinuation Total 9 703 RR=1.23 [0.83, 1.81] 6.77 (P = 0.24); 26% 8-52 Very Low
 a b e
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 Psychoeducation (47, 71, 72) 410 RR=1.41 [0.75, 2.64] 5.61 (P = 0.06); 64% 13-52  
 PE vs attention control (70) 120 No discontinuation  N/A 21  
 Mindfulness based cognitive 
therapy 
(76) 19 RR=2.91 [0.40, 21.35] 
 
N/A 8  
 Dialectical behaviour therapy (42) 26 RR=1.00 [0.07, 14.34] N/A 12  
 CBT (31, 74) 91 RR= 0.88 [0.37, 2.08] N/A (1 study no 
discontinuation) 
14  
 Social cognition and 
interaction training 
(77) 37 No discontinuation N/A 18  
 
3. Family psychoeducation vs Treatment as usual (TAU) 
 
Outcome (Sub-)analysis Trials 
(reference) 
N ES [95% CI] Heterogeneity: Chi² (p 
value); I² 
Inter
venti
on 
lengt
h 
(week
s) 
Quality 
(GRADE)(26) 
Depression symptoms Group Family PE (carers) (56) 43 SMD= -0.73 [-1.35, -0.10] N/A 14 Low
 d e
 
Mania symptoms Group Family PE (carers) (56) 43 SMD=  -0.66 [-1.28, -0.04] N/A 14 Low
 d e
 
Study Discontinuation Group Family PE (carers) (56) 46 RR=0.42 [0.04, 4.31] N/A 14 Low
 b d 
 
 
4. Collaborative care vs TAU 
 
Outcome (Sub-)analysis Trials 
(reference) 
N ES [95% CI] Heterogeneity: Chi² (p 
value); I² 
Inter
venti
on 
lengt
Quality 
(GRADE)(26) 
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h 
(week
s) 
Depression symptoms Physical health focus (52, 53) 123 SMD=-0.22 [-0.63, 0.19] 1.32 (P = 0.25); 24% 26-30 Low
 a d e
 
Mania symptoms Physical health focus (52, 53) 123 SMD=-0.07 [-0.47, 0.32] 1.24 (P = 0.27); 19% 26-30 Low
 a d e
 
Hospitalisation  Psychiatric focus (54, 83) 572 RR=0.68 [0.49, 0.94] 0.13 (P = 0.72); 0% 52-
130 
Moderate
 d
 
Relapse, any type  Psychiatric focus (54) 414 RR=0.99 [0.84, 1.17] N/A 52 Low
d e
 
Relapse, depression 
(number) 
Psychiatric focus (54, 83) 424 RR= 0.96 [0.80, 1.17] 0.48 (P = 0.49); 0% 52-
104 
Low
 d e
 
Relapse, mania  Psychiatric focus (54, 83) 505 RR= 0.93 [0.57, 1.52] 5.23 (P = 0.05); 81% 52-
104 
Very Low
b d e
 
Quality of life Total 2 379 SMD=-1.30 [-3.78, 1.18] 75.41 (P < 0.00001); 99% 30-
156 
Very Low
 a b d e
 
 Physical health focus (53) 65 SMD= -0.03 [-0.51, 0.46] N/A  30  
 Psychiatric focus (45) 314 SMD= -2.56 [-2.86, -2.26] N/A 156  
Study Discontinuation Total 4 997 RR= 0.99 [0.47, 2.07] 4.48 (P = 0.21); 33% 30-
156 
Low
 b d
 
 Physical health focus (53) 68 RR=2.00 [0.19, 21.03] N/A 30  
 Psychiatric focus 3(45, 54, 83) 929 RR= 0.96 [0.40, 2.30] 4.02 (P = 0.13); 50% 52-
156 
 
 
5. Integrated Cognitive and Interpersonal Therapy (IC&IT) vs Treatment as usual (TAU) 
 
Outcome (Sub-)analysis Trials 
(reference) 
N ES [95% CI] Heterogeneity: Chi² (p 
value); I² 
Inter
venti
on 
lengt
h 
Quality 
(GRADE)(26) 
47 
 
(week
s) 
Depression symptoms (IC&IT) vs TAU (92) 193 SMD=  -0.64 [-1.19, -0.09] N/A 20 Low
 d 
 
Mania symptoms (IC&IT) vs TAU (92) 193 SMD=  -0.10 [-0.30, 0.10] N/A 20 Low
 d e
 
Quality of life (IC&IT) vs TAU (92) 193 SMD=  -0.37 [-0.65, -0.08] N/A 20 Low
 d 
 
Study 
Discontinuation 
(IC&IT) vs TAU (92) 193 RR= 1.13 [0.47, 2.68] N/A 20 Low
 d 
 
 
6. Family Focused therapy (FFT) vs Active control 
 
Outcome (Sub-)analysis Trials 
(reference) 
N ES [95% CI] Heterogeneity: Chi² (p 
value); I² 
Inter
venti
on 
lengt
h 
(week
s) 
Quality 
(GRADE)(26) 
Depression symptoms FFT vs TAU (55) 79 SMD= -0.40 [-0.80, 0.00] N/A 39 Low
 a d
  
Mania symptoms FFT vs TAU (55) 79 SMD=  0.00 [-0.40, 0.40] N/A 39 Low
 a d
  
Relapse, any type  FFT vs PE (84) 53 RR= 0.89 [0.52, 1.54] N/A 39 Low
 d
  
Hospitalisation  FFT vs PE (84) 53 RR= 0.71 [0.33, 1.52] N/A 39 Low d 
Study Discontinuation Total 2 154 RR= 0.63 [0.21, 1.89] 1.99 (P = 0.16); 50% 39 Low
 b d
  
 FFT vs TAU (55) 101 RR= 0.36 [0.11, 1.12] N/A   
 FFT vs PE (84) 53 RR= 1.07 [0.37, 3.08] N/A   
 
7. Cognitive behaviour therapy (CBT) vs Active Control 
 
Outcome (Sub-)analysis Trials 
(reference) 
N ES [95% CI] Heterogeneity: Chi² (p 
value); I² 
Inter
venti
Quality 
(GRADE)(26) 
48 
 
on 
lengt
h 
(week
s) 
Depression symptoms CBT individual vs 
Supportive Therapy 
(ST) 
(85) 76 SMD= 0.41 [0.12, 0.70] N/A 39 Low
 d e
 
Mania symptoms CBT individual vs 
Supportive Therapy 
(ST) 
(85) 76 SMD=0.20 [-0.11, 0.51] N/A 39 Low
 d e
 
Relapse, any type CBT individual vs 
Supportive Therapy 
(ST) 
(85) 76 RR=0.60 [0.34, 1.05] N/A 39 Low
 d e 
 
Study Discontinuation CBT individual vs 
Supportive Therapy 
(ST) 
(85) 76 RR=0.80 [0.56, 1.14] N/A 39 Low
 d
 
 
8. Interpersonal and social rhythm therapy (IPSRT) vs Active control 
 
Outcome (Sub-)analysis Trials 
(reference) 
N ES [95% CI] Heterogeneity: Chi² (p 
value); I² 
Inter
venti
on 
lengt
h 
(week
s) 
Quality 
(GRADE)(26) 
Depression symptoms IPSRT vs Quetiapine (43) 25 SMD= 0.44 [-0.34, 1.22] N/A 12 Very Low
 a d
 
Relapse, any type  IPSRT vs Intensive (46) 41 RR= 1.55 [0.63, 3.84] N/A 123 Very Low
 a d
 
49 
 
clinical management  
Response, any type 
(number) 
IPSRT vs Quetiapine (43) 25 RR= 0.98 [0.60, 1.60] N/A 12 Very Low
 a d
 
Psychosocial functioning 
GAF 
IPSRT vs Quetiapine (43) 25 SMD= 0.55 [-0.26, 1.36] N/A 12 Very Low
 a d
 
Psychosocial functioning 
Social and/or Work   
IPSRT vs Intensive 
clinical management  
(46) 82 SMD= -0.36 [-0.72, 0.00] N/A 123 Very Low
 a d
 
Study Discontinuation Total 2 107 RR= 0.94 [0.55, 1.59] 0.07 (P = 0.79); 0% 12-
123 
Moderate
 d
 
 IPSRT vs Quetiapine (43) 25 RR= 0.79 [0.20, 3.16] N/A 12  
 IPSRT vs Intensive 
clinical management  
(46) 82 RR= 0.96 [0.54, 1.71] N/A 123  
 
9. Integrated group therapy  (IGT) vs Active control 
 
Outcome (Sub-)analysis Trials 
(reference) 
N ES [95% CI] Heterogeneity: Chi² (p 
value); I² 
Inter
venti
on 
lengt
h 
(week
s) 
Quality 
(GRADE)(26) 
Depression symptoms IGT vs group drug 
counselling 
(57) 61 SMD= -0.35 [-0.85, 0.16] N/A 12 Very Low
 c d e
 
Mania symptoms IGT vs group drug 
counselling 
(57) 61 SMD= -0.17 [-0.68, 0.33] N/A 12 Very Low
 c d e 
 
 
a  Risk of bias, b Inconsistency, c Indirectness, d Imprecision, e Publication/Reporting Bias  
TAU = Treatment as usual; CBT = Cognitive behaviour therapy; PE= Psychoeducation 
N/A = not applicable; SMD = Standardised mean difference ; RR = Risk Ratio;  
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Table 9  Outcomes at follow-up 
 
 
 
 
1. Individual psychological intervention vs Treatment as usual (TAU) 
 
Outcome (Sub-)analysis Trials 
(reference) 
N ES [95% CI] Heterogeneity: Chi² (p 
value); I² 
Follo
w-up 
perio
d 
(week
s) 
Quality 
(GRADE)(26) 
Depression symptoms Total 5 534 SMD= -0.21 [-0.43, 0.01] 6.85 (P = 0.23); 27% 26-52 Low
 a 
 
 Online Psychoeducation (58, 59)  326 SMD= -0.36 [-1.09, 0.37] 5.82 (P = 0.02); 83% 26-43  
51 
 
 CBT (33, 64, 66, 
67) 
208 SMD= -0.19 [-0.46, 0.08] 0.64 (P = 0.73); 0% 52  
Mania symptoms Total 4 164 SMD=-0.38 [-0.71, -0.04] 3.40 (P = 0.33); 12% 52 Very Low
 a d e
 
 Online Psychoeducation (59) 37 SMD=-0.24 [-0.89, 0.40] N/A 43  
 CBT (64, 66, 67) 127 SMD=-0.45 [-0.92, 0.01] 3.21 (P = 0.34); 38% 52  
Hospitalisation  Total 3 194 RR= 0.63 [0.38, 1.02] 2.19 (P = 0.35); 9% 32-52 Low
 d
 
 Psychoeducation (63) 70 RR= 0.85 [0.47, 1.54] N/A 52  
 Medication adherence 
therapy 
(68) 28 RR= 0.40 [0.09, 1.73] N/A 32  
 CBT (67) 96 RR= 0.44 [0.20, 0.97] N/A 52  
Relapse, any type  Total 8 532 RR= 0.74 [0.63, 0.87] 5.78 (P = 0.57); 0% 32-78 Moderate
 d
 
 Psychoeducation (61-63) 252 RR= 0.81 [0.64, 1.02] 1.96 (P = 0.37); 0% 48-78  
 Medication adherence 
therapy 
(68) 28 RR= 0.73 [0.43, 1.24] N/A 32  
 CBT (33, 64, 65, 
67) 
252 RR= 0.67 [0.53, 0.86] 2.84 (P = 0.42); 0% 52  
Relapse, depression  Total 7 616 RR= 0.82 [0.59, 1.15] 14.84, (P = 0.02); 
60% 
43-72 Low
 b d
 
 Psychoeducation (62, 63) 166 RR=1.07 [0.53, 2.14] 2.87 (P = 0.09); 65% 48-52  
 Online Psychoeducation (59) 37 RR=1.31 [0.70, 2.45] N/A 43  
 CBT (33, 51, 64, 
67) 
413 RR=0.65 [0.41, 1.02] 7.95 (P = 0.05); 62% 52-72  
Relapse, mania  Total 6 564 RR= 0.74 [0.50, 1.08] 7.92 (P = 0.16); 37% 43-72 Low
 b d
 
 Psychoeducation (62, 63) 166 RR=0.56 [0.28, 1.11] 1.36 (P = 0.24); 27% 48-52  
 Online Psychoeducation (59) 37 RR=0.94 [0.30, 2.96] N/A 43  
 CBT (33, 51, 67) 361 RR= 0.78 [0.45, 1.38] 4.65 (P = 0.10); 57% 52-72  
Response, any  CBT (64) 52 RR=0.46 [0.21, 1.02] N/A 52 Very Low
 a d 
 
Response, depression  CBT (41, 64) 257 RR= 0.69 [0.40, 1.13] 2.23 (P = 0.14); 55% 52 Very Low
 a b d
 
52 
 
Response, mania  CBT (64) 52 RR= 1.53 [0.93, 2.52] N/A 52 Very Low
 a d 
 
Quality of life Total 3 347 SMD= 0.04 [-0.17, 0.25] 1.44 (P = 0.49); I² = 
0% 
26-52 Very Low
 a d e
 
 Online Psychoeducation (58, 59) 310 SMD= 0.08 [-0.14, 0.31] 0.02 (P = 0.90); I² = 
0% 
26-43  
 CBT (33) 37 SMD= -0.34 [-1.00, 0.32] N/A 52  
Psychosocial functioning GAF Total 2 89 SMD=-0.25 [-0.66, 0.17] 0.00 (P = 0.98); 0% 43-52 Low
 a d
 
 Online Psychoeducation (59) 37 SMD=-0.25 [-0.90, 0.40] N/A 43  
 CBT (64) 52 SMD=-0.24 [-0.79, 0.31] N/A 52  
Psychosocial functioning  
Social and/or Work 
Total 8 585 SMD= -0.27 [-0.60, 0.05] 18.39 (P = 0.005); 
67% 
26-52 Very  
Low
 a b d e
 
 Psychoeducation (62, 63) 70 SMD= -0.74 [-1.23, -0.26] N/A 52  
 Online Psychoeducation (58, 59) 310 SMD= 0.08 [-0.14, 0.30] 0.32 (P = 0.57); 0% 26-43  
 CBT (33, 64, 66, 
67) 
205 SMD= -0.39 [-0.78, 0.01] 5.36 (P = 0.15); 44% 52  
Study Discontinuation Total 12 1163 RR= 0.97 [0.77, 1.23] 10.21 (P = 0.42); 2% 32-78 Low d 
 Psychoeducation (61-63) 274 RR= 1.26 [0.29, 5.58] 3.46 (P = 0.18); 42% 48-78  
 Online Psychoeducation (58, 59) 330 RR= 0.85 [0.28, 2.56] 1.54  (P = 0.22); 35% 26-43  
 Medication adherence 
therapy 
(68) 28 No discontinuation N/A 32  
 CBT (33, 41, 64-
67) 
531 RR= 0.98 [0.74, 1.30] 5.47 (P = 0.36); 9% 52  
 
2. Group psychological intervention vs Treatment as usual (TAU) 
 
Outcome (Sub-)analysis Trials 
(reference) 
N ES [95% CI] Heterogeneity: Chi² (p 
value); I² 
Follo
w-up 
perio
d 
Quality 
(GRADE) (26) 
53 
 
(week
s) 
Depression symptoms Total 3 219 SMD= 0.22 [-0.05, 0.49] 0.95 (P = 0.62); 0% 52-61 Very Low
 a d e
 
 Psychoeducation (72) 72 SMD=0.40 [-0.07, 0.87] N/A 52  
 CBT (31) 52 SMD=0.06 [-0.48, 0.60] N/A 52  
 Mindfulness based 
cognitive therapy 
(75) 95 SMD=0.18 [-0.22, 0.58] N/A 61  
Mania symptoms Total 3 219 SMD= 0.16 [-0.10, 0.43] 0.76 (P = 0.68); 0% 52-61 Very Low
 a d e
 
 Psychoeducation (72) 72 SMD= 0.33 [-0.14, 0.80] N/A 52  
 CBT (31) 52 SMD= 0.12 [-0.42, 0.66] N/A 52  
 Mindfulness based 
cognitive therapy 
(75) 95 SMD=  0.06 [-0.34, 0.46] N/A 61  
Hospitalisation  Total 3 200 RR= 0.48 [0.16, 1.45] 2.30 (P = 0.13); 56% 78-
124 
Very Low
 b d e
 
 PE vs attention control (69, 70) 166 RR=0.48 [0.16, 1.45] 2.30  (P = 0.13; 56% 124  
 CBT (73) 34 No hospitalisations N/A 78  
Relapse, any type  Total 5 395 RR= 0.86 [0.61, 1.20] 21.46 (P = 0.0003); 
81% 
52-
124 
Very Low
 b d e
 
 Psychoeducation (72) 84 RR= 0.52 [0.32, 0.84] N/A 52  
 PE vs attention control (69, 70) 166 RR= 0.75 [0.64, 0.88] 0.83 (P = 0.36); 0%  124  
 Mindfulness based 
cognitive therapy 
(75) 95 RR=1.41 [1.07, 1.87] N/A 61  
 CBT (73) 50 RR= 1.17 [0.72, 1.91]  N/A 78  
Relapse, depression  Total 5 333 RR= 0.62 [0.45, 0.88] 7.12 (P = 0.13); 44% 52-
124 
Low
 b d 
 
 Psychoeducation (72) 72 RR=0.33 [0.12, 0.91] N/A 52  
 PE vs attention control (69, 70) 166 RR=0.54 [0.36, 0.79] 1.25 (P = 0.26); 20% 124  
 Mindfulness based 
cognitive therapy 
(75) 59 RR= 0.87 [0.59, 1.28] N/A 61  
54 
 
 CBT (73) 36 RR=0.87 [0.41, 1.82] N/A 78  
Relapse, mania  Total 5 328 RR= 0.97 [0.60, 1.57] 13.04 (P = 0.01); 69% 52-
124 
Very Low
 a b d
 
 Psychoeducation (72) 72 RR= 1.02 [0.48, 2.16] N/A 52  
 PE vs attention control (69, 70) 166 RR= 0.64 [0.54, 0.76] 0.59 (P = 0.44); 0% 124  
 Mindfulness based 
cognitive therapy 
(75) 54 RR= 1.21 [0.71, 2.07] N/A 61  
 CBT (73) 36 RR= 2.61 [0.80, 8.52] N/A 78  
Relapse, mixed episode  Total 4 274 RR= 0.48 [0.30, 0.77] 2.38  (P = 0.50); 0% 52-
124 
Low
 b d
 
 Psychoeducation (72) 72 RR= 1.25 [0.08, 19.22] N/A 52  
 PE vs attention control (69, 70) 166 RR= 0.43 [0.26, 0.71] 0.01 (P = 0.93); 0% 124  
 CBT (73) 36 RR= 2.24 [0.22, 22.51] N/A 78  
Quality of life CBT (31) 52 SMD= 0.30 [-0.25, 0.84] N/A 52 Very Low a d  
Psychosocial functioning GAF CBT (31) 52 SMD= 0.67 [0.11, 1.23] N/A 52 Very Low
 a d 
 
Study Discontinuation Total 3 322 RR= 1.85 [0.53, 6.43] 1.85 (P = 0.09); 55% 52-
124 
Very Low
 b d e
 
 Psychoeducation (72) 84 RR= 5.00 [1.17, 21.46] N/A 52  
 PE vs attention control (70) 120 RR= 9.00 [0.50, 163.58] N/A 124  
 CBT (31, 73) 118 RR= 0.83[0.37, 1..81] 0.10 (P = 0.66); 0% 52-78  
 
3. Family psychoeducation (PE) vs Treatment as usual (TAU) 
 
Outcome (Sub-)analysis Trials 
(reference) 
N ES [95% CI] Heterogeneity: Chi² (p 
value); I² 
Follo
w-up 
perio
d 
(week
s) 
Quality 
(GRADE)(26) 
55 
 
Depression symptoms PE (Service user and 
carers) 
(78) 53 SMD= -0.15 [-0.69, 0.39] N/A 60 Very Low
 a d e
 
Mania symptoms PE (Service user and 
carers) 
(78) 53 SMD=  -0.78 [-1.34, -0.22] N/A 60 Very Low
 a d e
 
Hospitalisation  PE (Service user and 
carers) 
(79) 57 RR= 0.05 [0.00, 0.83] N/A 60 Low
 d 
 
Relapse, any type  Total 3 228 RR=0.52 [0.32, 0.84] 2.61 (P = 0.27); 23% 52-65 Low 
d e
 
 PE (Service user and 
carers) 
(78) 58 RR=0.26 [0.08, 0.83] N/A 60  
 Group Family PE 
(carers) 
(79, 81) 170 RR=0.61 [0.44, 0.86] 0.50 (P = 0.48); 0% 52-65  
Relapse, depression Group Family PE 
(carers) 
(81) 113 RR= 0.73 [0.44, 1.21] N/A 65 Low
 d e
 
Relapse, mania Group Family PE 
(carers) 
(81) 113 RR= 0.35 [0.15, 0.85] N/A 65 Low
 d
 
Relapse, mixed episode  Group Family PE 
(carers) 
(81) 113 RR= 0.20 [0.01, 4.00] N/A 65 Very Low
 d e
 
Response, any PE (Service user and 
carers) 
(48) 59 RR= 0.67 [0.34, 1.32] N/A 121 Very Low
 a d 
 
Response, mania  PE (Service user and 
carers) 
(48) 59 RR= 0.79 [0.46, 1.33] N/A 121 Very Low
 a d 
 
Quality of life Group Family PE 
(carers) 
2 arms of 
(80) 
35 SMD= -0.63 [-1.44, 0.18] 0.22 (P = 0.64); I² = 
0% 
57 Very Low
 a d 
 
Psychosocial functioning GAF Group Family PE 
(carers) 
2 arms of 
(80) 
35 SMD= -1.03 [-1.86, -0.19] 0.01 (P = 0.93); I² = 
0% 
57 Very Low
 a d 
 
Study Discontinuation Group Family PE 
(carers) 
(79-81) 217 RR= 1.02 [0.38, 2.74] 0.37 (P = 0.95); I² = 
0% 
31-65 Very Low
d e
 
 
4. Collaborative care vs TAU 
56 
 
 
Outcome (Sub-)analysis Trials 
(reference) 
N ES [95% CI] Heterogeneity: Chi² (p 
value); I² 
Follo
w-up 
perio
d 
(week
s) 
Quality 
(GRADE)(26) 
Depression symptoms Physical health focus (53) 65 SMD= -0.56 [-1.06, -0.07] N/A 52 Very Low
 a d
 
Mania symptoms Physical health focus (53) 65 SMD= -0.10 [-0.59, 0.38] N/A 52 Very Low
 a d
 
Quality of life Physical health focus (53) 65 SMD=  -0.38 [-0.87, 0.11] N/A  52 Very Low
 a d
 
Study Discontinuation Physical health focus (53) 68 RR=2.00 [0.19, 21.03] N/A 52 Low
 a d
 
 
6. Family Focused therapy (FFT) vs (active) control 
 
Outcome (Sub-)analysis Trials 
(reference) 
N ES [95% CI] Heterogeneity: Chi² (p 
value); I² 
Follo
w-up 
perio
d 
(week
s) 
Quality 
(GRADE)(26) 
Depression symptoms FFT vs TAU (55) 79 SMD= -0.10 [-0.56, 0.36] N/A 52 Very Low
 a d 
 
Mania symptoms FFT vs TAU (55) 79 SMD= -0.30 [-0.68, 0.08] N/A 52 Very Low
 a d 
 
Relapse, any type  FFT vs TAU (55) 101 RR= 0.67 [0.34, 1.30] N/A 52 Very Low
 a d 
 
Response, any  FFT vs TAU (48) 62 RR=  1.15 [0.68, 1.94] N/A 121 Very Low
 a d 
 
Response, depression  FFT vs TAU (41) 156 RR= 0.48 [0.23, 0.98] N/A 52 Very Low
 a d 
 
Response, mania  FFT vs TAU (48) 62 RR=1.15 [0.76, 1.75] N/A 121 Very Low
 a d 
 
Hospitalisation  FFT vs PE (84) 38 RR= 0.24 [0.08, 0.74] N/A 104 Very Low
 a d
 
Study Discontinuation FFT vs TAU (41, 48, 55) 144 RR= 0.63 [0.26, 1.50] 1.83 (P = 0.18); 45% 52-
121 
Low
 d
 
57 
 
 
7. Cognitive behaviour therapy (CBT) vs Active Control 
 
Outcome (Sub-)analysis Trials 
(reference) 
N ES [95% CI] Heterogeneity: Chi² (p 
value); I² 
Follo
w-up 
perio
d 
(week
s) 
Quality 
(GRADE)(26) 
Depression symptoms CBT individual vs 
Supportive Therapy  
(85) 76 SMD= 0.49 [0.04, 0.94] N/A 143 Very Low
 d  e
 
Relapse, any type  CBT individual vs 
Supportive Therapy  
(85) 76 RR= 1.13 [0.81, 1.58] N/A 143 Very Low
 d e
 
Relapse, depression  CBT individual vs 
Supportive Therapy  
(85) 76 RR=  1.12 [0.69, 1.80] N/A 143 Very Low
 d e
 
Relapse, mania  CBT individual vs 
Supportive Therapy  
(85) 76 RR=  1.67 [0.96, 2.91] N/A 143 Very Low
 d e
 
Relapse, mixed episode CBT individual vs 
Supportive Therapy  
(85) 76 RR=  0.33 [0.01, 7.93] N/A 143 Very Low
 d e
 
Study Discontinuation CBT individual vs 
Supportive Therapy  
(85) 76 No discontinuation N/A 143 - 
 
8. Interpersonal and social rhythm therapy (IPSRT) vs Active control 
 
Outcome (Sub-)analysis Trials 
(reference) 
N ES [95% CI] Heterogeneity: Chi² (p 
value); I² 
Follo
w-up 
perio
d 
(week
Quality 
(GRADE)(26) 
58 
 
s) 
Response, depression  IPRST vs TAU (41) 192 RR= 0.73 [0.50, 1.07] N/A 52 Very Low
 a d 
 
Study Discontinuation IPRST vs TAU (41) 193 RR= 1.05 [0.67, 1.63] N/A 52 Low
 d
  
 
9. Integrated group therapy vs Active control 
 
Outcome (Sub-)analysis Trials 
(reference) 
N ES [95% CI] Heterogeneity: Chi² (p 
value); I² 
Follo
w-up 
perio
d 
(week
s) 
Quality 
(GRADE)(26) 
Depression symptoms IGT vs group drug 
counselling 
(57) 61 SMD=  0.11 [-0.39, 0.61] N/A 26 Very Low
 c d e
 
Mania symptoms IGT vs group drug 
counselling 
(57) 61 SMD=  -0.53 [-1.05, -0.02] N/A 26 Very Low
 c d e
 
 
a  Risk of bias, b Inconsistency, c Indirectness, d Imprecision, e Publication/Reporting Bias  
TAU = Treatment as usual; CBT = Cognitive behaviour therapy; PE= Psychoeducation 
N/A = not applicable; SMD = Standardised mean difference ; RR = Risk Ratio;  
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